WO2010094120A1 - Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase - Google Patents
Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase Download PDFInfo
- Publication number
- WO2010094120A1 WO2010094120A1 PCT/CA2010/000218 CA2010000218W WO2010094120A1 WO 2010094120 A1 WO2010094120 A1 WO 2010094120A1 CA 2010000218 W CA2010000218 W CA 2010000218W WO 2010094120 A1 WO2010094120 A1 WO 2010094120A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- group
- independently selected
- Prior art date
Links
- 0 Cc1nnn[n]1* Chemical compound Cc1nnn[n]1* 0.000 description 25
- XUOPPVRVRLKAFV-UHFFFAOYSA-N CC(C1)(Oc(cccc2)c2C1=O)I Chemical compound CC(C1)(Oc(cccc2)c2C1=O)I XUOPPVRVRLKAFV-UHFFFAOYSA-N 0.000 description 2
- XFXBWEMTHDVUIY-UHFFFAOYSA-N OC(C[n]1nnc(-c2cc(N(CC3)CCC3(CC3)Oc4c3c(Cl)ccc4)n[o]2)n1)=O Chemical compound OC(C[n]1nnc(-c2cc(N(CC3)CCC3(CC3)Oc4c3c(Cl)ccc4)n[o]2)n1)=O XFXBWEMTHDVUIY-UHFFFAOYSA-N 0.000 description 2
- WRJOQYNCPVXGGP-UHFFFAOYSA-N OC(C[n]1nnc(-c2cnc(N(CC3)CCC3(CC3=O)Oc4c3c(Cl)ccc4)[s]2)n1)=O Chemical compound OC(C[n]1nnc(-c2cnc(N(CC3)CCC3(CC3=O)Oc4c3c(Cl)ccc4)[s]2)n1)=O WRJOQYNCPVXGGP-UHFFFAOYSA-N 0.000 description 2
- DUTNTKTZIQAPGA-UHFFFAOYSA-N CC(C)(C1)Oc(cccc2)c2C1=O Chemical compound CC(C)(C1)Oc(cccc2)c2C1=O DUTNTKTZIQAPGA-UHFFFAOYSA-N 0.000 description 1
- DKZMKZLFITYAAP-UHFFFAOYSA-N CC(CC1)(OC2=C1C=CCC2)I Chemical compound CC(CC1)(OC2=C1C=CCC2)I DKZMKZLFITYAAP-UHFFFAOYSA-N 0.000 description 1
- JWTILJNGAXVONV-UHFFFAOYSA-N CC(Cc1ccccc11)(OC1=O)I Chemical compound CC(Cc1ccccc11)(OC1=O)I JWTILJNGAXVONV-UHFFFAOYSA-N 0.000 description 1
- IAUVESOXDUFHJQ-UHFFFAOYSA-N CCOC(C[n]1nnc(-c([s]2)cnc2Br)n1)=O Chemical compound CCOC(C[n]1nnc(-c([s]2)cnc2Br)n1)=O IAUVESOXDUFHJQ-UHFFFAOYSA-N 0.000 description 1
- FLDHTKBTJPRKOY-UHFFFAOYSA-N C[O]1c2ccccc2CCC1(S)I Chemical compound C[O]1c2ccccc2CCC1(S)I FLDHTKBTJPRKOY-UHFFFAOYSA-N 0.000 description 1
- ZGNDLGFUYNRRBQ-UHFFFAOYSA-N Cc1cccc2c1CCC(CC1)(CCN1c1ncc(-c3n[n](CC(O)=O)nn3)[s]1)O2 Chemical compound Cc1cccc2c1CCC(CC1)(CCN1c1ncc(-c3n[n](CC(O)=O)nn3)[s]1)O2 ZGNDLGFUYNRRBQ-UHFFFAOYSA-N 0.000 description 1
- LVILGAOSPDLNRM-UHFFFAOYSA-N Cc1ccncn1 Chemical compound Cc1ccncn1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N Cc1n[nH]nn1 Chemical compound Cc1n[nH]nn1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
- IEQIMOZHZBUISS-UHFFFAOYSA-N N/C(/c1nnc(N(CC2)CCC2(CC2=O)Oc3c2c(Cl)ccc3)[s]1)=N\N(CC(O)=O)N Chemical compound N/C(/c1nnc(N(CC2)CCC2(CC2=O)Oc3c2c(Cl)ccc3)[s]1)=N\N(CC(O)=O)N IEQIMOZHZBUISS-UHFFFAOYSA-N 0.000 description 1
- HVMMNIOHLRIAOO-UHFFFAOYSA-N O=C(CC1(CCNCC1)Oc1ccc2)c1c2Br Chemical compound O=C(CC1(CCNCC1)Oc1ccc2)c1c2Br HVMMNIOHLRIAOO-UHFFFAOYSA-N 0.000 description 1
- FMUOWTCJDBKUJN-UHFFFAOYSA-N OC(C[n]1nnc(-c2cc(N(CC3)CCC3(CC3=O)Oc4c3c(Cl)ccc4)n[o]2)n1)=O Chemical compound OC(C[n]1nnc(-c2cc(N(CC3)CCC3(CC3=O)Oc4c3c(Cl)ccc4)n[o]2)n1)=O FMUOWTCJDBKUJN-UHFFFAOYSA-N 0.000 description 1
- ZTAJDWVTNCBVNS-UHFFFAOYSA-N OC(C[n]1nnc(-c2cnc(N(CC3)CCC3(C3)Oc(cccc4)c4C3=O)[s]2)n1)=O Chemical compound OC(C[n]1nnc(-c2cnc(N(CC3)CCC3(C3)Oc(cccc4)c4C3=O)[s]2)n1)=O ZTAJDWVTNCBVNS-UHFFFAOYSA-N 0.000 description 1
- AXMOLBLFTAUXGI-UHFFFAOYSA-N OC(C[n]1nnc(-c2nnc(N(CC3)CCC3(CC3)Oc4c3c(Cl)ccc4)[s]2)n1)=O Chemical compound OC(C[n]1nnc(-c2nnc(N(CC3)CCC3(CC3)Oc4c3c(Cl)ccc4)[s]2)n1)=O AXMOLBLFTAUXGI-UHFFFAOYSA-N 0.000 description 1
- XRAIYSXKZNDTRF-UHFFFAOYSA-N OC(C[n]1nnc(-c2nnc(N(CC3)CCC3(CCc3ccc4)Oc3c4Cl)[s]2)n1)=O Chemical compound OC(C[n]1nnc(-c2nnc(N(CC3)CCC3(CCc3ccc4)Oc3c4Cl)[s]2)n1)=O XRAIYSXKZNDTRF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Definitions
- the present invention relates to heteroaromatic compounds which are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) and the use of such compounds to control, prevent and/or treat conditions or diseases mediated by SCD activity.
- SCD stearoyl-coenzyme A delta-9 desaturase
- the compounds of the present invention are useful for the control, prevention and treatment of conditions and diseases related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; cancer; and hepatic steatosis.
- At least three classes of fatty acyl-coenzyme A (CoA) desaturases (delta-5, delta-6 and delta-9 desaturases) are responsible for the formation of double bonds in mono- and polyunsaturated fatty acyl-CoAs derived from either dietary sources or de novo synthesis in mammals.
- the delta-9 specific stearoyl-CoA desaturases (SCDs) catalyze the rate-limiting formation of the cis-double bond at the C9-C10 position in monounsaturated fatty acyl-CoAs.
- the preferred substrates are stearoyl-CoA and palmitoyl-CoA, with the resulting oleoyl and palmitoleoyl-CoA as the main components in the biosynthesis of phospholipids, triglycerides, cholesterol esters and wax esters (Dobrzyn and Natami, Obesity Reviews, 6: 169-174 (2005)).
- the rat liver microsomal SCD protein was first isolated and characterized in 1974 (Strittmatter et al., PNAS, 71: 4565-4569 (1974)).
- a number of mammalian SCD genes have since been cloned and studied from various species. For example, two genes have been identified from rat (SCDl and SCD2, Thiede et al., J. Biol. Chem.. 261, 13230-13235 (1986)), Mihara, K., J. Biochem. (Tokyo), 108: 1022-1029 (1990)); four genes from mouse (SCDl, SCD2, SCD3 and SCD4) (Miyazaki et al., J. Biol.
- ASO inhibition of SCD activity reduced fatty acid synthesis and increased fatty acid oxidation in primary mouse hepatocytes.
- Treatment of mice with SCD-ASOs resulted in the prevention of diet-induced obesity, reduced body adiposity, hepatomegaly, steatosis, postprandial plasma insulin and glucose levels, reduced de novo fatty acid synthesis, decreased the expression of lipogenic genes, and increased the expression of genes promoting energy expenditure in liver and adipose tissues.
- SCD inhibition represents a novel therapeutic strategy in the treatment of obesity and related metabolic disorders.
- the postprandial de novo lipogenesis is significantly elevated in obese subjects (Marques-Lopes, et al., American Journal of Clinical Nutrition, 73: 252-261 (2001)).
- Knockout of the SCD gene ameliorates Metabolic Syndrome by reducing plasma triglycerides, reducing weight gain, increasing insulin sensitivity, and reduces hepatic lipid accumulation (MacDonald, et al., Journal of Lipid Research, 49(1): 217-29 (2007)).
- There is a significant correlation between a high SCD activity and an increased cardiovascular risk profile including elevated plasma triglycerides, a high body mass index and reduced plasma HDL (Attie, et al., J. Lipid Res., 43 : 1899- 1907 (2002)).
- SCD activity plays a key role in controlling the proliferation and survival of human transformed cells (Scaglia and Igal, J. Biol. Chem., (2005)). RNA interference of SCD-I reduces human tumor cell survival (Morgan-Lappe, et al., Cancer Research. 67(9): 4390-4398 (2007)).
- inhibitors of SCD activity include non-selective thia-fatty acid substrate analogs [B. Behrouzian and P.H. Buist,
- SCD inhibitors are also disclosed in the following published international patent application publications: WO 2008/074835; WO 2008/074824; WO 2008/036715; WO 2008/044767; WO 2008/029266; WO 2008/062276; and WO 2008/127349.
- a number of international patent applications assigned to Merck Frosst Canada Ltd. that disclose SCD inhibitors useful for the treatment of obesity and Type 2 diabetes have also published: WO 2006/130986 (14 Dec. 2006); WO 2007/009236 (25 Jan. 2007); WO 2007/056846 (24 May 2007); WO 2007/071023 (28 June 2007); WO 2007/134457 (29 November 2007); WO 2007/143823 (21 Dec. 2007); WO 2007/143824 (21 Dec. 2007); WO 2008/017161 (14 Feb. 2008); WO 2008/046226 (24 April 2008); WO 2008/064474 (5 June 2008); and US 2008/0182838 (31 July 2008).
- WO 2008/003753 (assigned to Novartis) discloses a series of pyrazolo[l,5- ⁇ ]pyrimidine analogs as SCD inhibitors; WO 2007/143697 and WO 2008/024390 (assigned to Novartis and Xenon Pharmaceuticals) disclose heterocyclic derivatives as SCD inhibitors; and WO
- the present invention is concerned with novel heteroaromatic compounds as inhibitors of stearoyl-CoA delta-9 desaturase which are useful in the treatment and/or prevention of various conditions and diseases mediated by SCD activity including those related, but not limited, to elevated lipid levels, as exemplified in non-alcoholic fatty liver disease, cardiovascular disease, obesity, diabetes, metabolic syndrome, and insulin resistance.
- the present invention relates to heteroaromatic compounds of structural formula I:
- heteroaromatic compounds are effective as inhibitors of SCD. They are therefore useful for the treatment, control or prevention of disorders responsive to the inhibition of SCD, such as diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, and cancer.
- the present invention also relates to pharmaceutical compositions comprising the compounds of the present invention and a pharmaceutically acceptable carrier.
- the present invention also relates to methods for the treatment, control, or prevention of disorders, diseases, or conditions responsive to inhibition of SCD in a subject in need thereof by administering the compounds and pharmaceutical compositions of the present invention.
- the present invention also relates to methods for the treatment, control, or prevention of Type 2 diabetes, insulin resistance, obesity, lipid disorders, atherosclerosis, metabolic syndrome, and cancer by administering the compounds and pharmaceutical compositions of the present invention.
- the present invention also relates to methods for the treatment, control, or prevention of obesity by administering the compounds of the present invention in combination with a therapeutically effective amount of another agent known to be useful to treat the condition.
- the present invention also relates to methods for the treatment, control, or prevention of Type 2 diabetes by administering the compounds of the present invention in combination with a therapeutically effective amount of another agent known to be useful to treat the condition.
- the present invention also relates to methods for the treatment, control, or prevention of insulin resistance by administering the compounds of the present invention in combination with a therapeutically effective amount of another agent known to be useful to treat the condition.
- the present invention also relates to methods for the treatment, control, or prevention of atherosclerosis by administering the compounds of the present invention in combination with a therapeutically effective amount of another agent known to be useful to treat the condition.
- the present invention also relates to methods for the treatment, control, or prevention of lipid disorders by administering the compounds of the present invention in combination with a therapeutically effective amount of another agent known to be useful to treat the condition.
- the present invention also relates to methods for the treatment, control, or prevention of metabolic syndrome by administering the compounds of the present invention in combination
- the present invention also relates to methods for the treatment, control, or prevention of cancer by administering the compounds of the present invention in combination with a therapeutically effective amount of another agent known to be useful to treat the condition.
- the present invention is concerned with heteroaromatic compounds useful as inhibitors of SCD.
- Compounds of the present invention are described by structural formula I:
- A is selected from the group consisting of:
- g is a single bond or a double bond
- J and K are each independently selected from the group consisting of: S, O, NH, CH and CH2, wherein each NH is unsubstituted or substituted with Rg, and wherein each CH and CH2 is unsubstituted or substituted with R2, provided that when g is a single bond at least one of J and K is CH2 unsubstituted or substituted with R2, and further provided that when g is a double bond then both J and K are CH;
- L and M are each independently selected from the group consisting of: S, O, NH and CH2, wherein each NH is unsubstituted or substituted with Rg, and wherein each CH2 is unsubstituted or substituted with R2;
- T, U, V and W are each independently selected from N and CH, wherein each CH is unsubstituted or substituted with R.3, provided that at least two of T, U, V and W are CH;
- X is CH2, wherein CH2 is unsubstituted or substituted with R.2;
- Y is independently selected from the group consisting of: O, NH and CH2, wherein each NH is unsubstituted or substituted with Rg, and wherein each CH2 is unsubstituted or substituted with
- Z is independently selected from the group consisting of: S, S(O), S(O)2, O, NH and CH2, wherein each NH is unsubstituted or substituted with Rg, and wherein each CH2 is unsubstituted or substituted with R2;
- B is a 5 membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from NH, O and S, wherein any CH is unsubstituted or substituted with one substituent selected from R a , and wherein any NH is unsubstituted or substituted with one substituent selected from Rb;
- each Rl is independently selected from the group consisting of: hydrogen, halogen, and C 1.3 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents independently selected from halogen and hydroxy;
- each R2 is independently selected from the group consisting of:
- alkyl is unsubstituted or substituted with hydroxy or one to three halogens, and wherein any CH2 in R2 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C] .4 alkyl unsubstituted or substituted with one to five fluorines;
- each R3 is independently selected from the group consisting of:
- alkyl is unsubstituted or substituted with one to three substituents selected from: hydroxy, halogen, C 1-4 alkyl, C3.6 cycloalkyl, C 2 -5 cycloheteroalkyl, aryl, and heteroaryl wherein alkyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are unsubstituted or substituted with one to three substituents selected from: halogen, hydroxy, and Cl .4 alkyl unsubstituted or substituted with one to five fluorines, and wherein any CH 2 in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Cl .4 alkyl unsubstituted or substituted with one to five fluorines;
- R4 is selected from the group consisting of:
- each R a is independently selected from the group consisting of:
- each Rb is independently selected from the group consisting of:
- each Re is independently selected from the group consisting of:
- each Rd is independently selected from the group consisting of:
- each R e is independently selected from the group consisting of:
- alkyl is unsubstituted or substituted with one to three substituents independently selected from the group consisting of: halogen, cyano, -Ci .4 alkoxy, -Ci .4 alkylthio, -C 1.4 alkylsulfonyl, -CO2H, and -CO2C1-4 alkyl;
- each Rg is independently selected from the group consisting of:
- n is an integer from 0 to 3
- p is an integer from 1 to 3
- q is an integer from 1 to 2
- t is an integer from 0 to 8
- d is an integer from 0 to 2
- e is an integer from 0 to 2, provided that d + e is 2.
- A is selected from the group consisting of:
- A is selected from the group consisting of:
- A is selected from the group consisting of:
- A is selected from the group consisting of:
- A is selected from the group consisting of:
- A is selected from the group consisting of:
- A is selected from the group consisting of:
- A is selected from the group consisting of:
- A is:
- A is:
- A is:
- A In another class of this embodiment, A is: In another class of this embodiment, A is: In another class of this embodiment, A is:
- A is selected from the group consisting of:
- B is a 5-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from NH, O and S, wherein any CH is unsubstituted or substituted with one substituent selected from Ra, and wherein any NH is unsubstituted or substituted with one substituent selected from Rb.
- B is a 5-membered heteroaryl ring containing 2 or 3 heteroatoms selected from NH, O and S, wherein any CH is unsubstituted or substituted with one substituent selected from R a , and wherein NH is unsubstituted or substituted with one substituent selected from Rb.
- B is selected from the group consisting of:
- B is selected from the group consisting of:
- B is selected from the group consisting of:
- B is selected from the group consisting of:
- B is selected from the group consisting of: In another class of this embodiment, B is selected from the group consisting of:
- B-R 4 is selected from the group consisting of:
- B-R is
- B-R 4 is N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl-N-phenyl
- B-R 4 is
- B-R 4 is selected from the group consisting of:
- B-R is
- J and K are each independently selected from the group consisting of: S, O, NH, CH and CH2, wherein each NH is unsubstituted or substituted with Rg, and wherein each CH and CH2 is unsubstituted or substituted with R2, provided that when g is a single bond at least one of J and K is CH2 unsubstituted or substituted with R2, and further provided that when g is a double bond then both J and K are CH.
- J and K are each independently selected from the group consisting of: O, NH, CH and CH2, wherein each NH is unsubstituted or substituted with Rg, and wherein each CH and CH2 is unsubstituted or substituted with R2, provided that when g is a single bond at least one of J and K is CH2 unsubstituted or substituted with R.2, and further provided that when g is a double bond then both J and K are CH.
- g is a single bond
- J is O and K is CH2, wherein CH2 is unsubstituted or substituted with R.2.
- g is a single bond, J is CH2 and K is O, wherein CH2 is unsubstituted or substituted with R.2.
- g is a single bond, J is CH2 and K is O.
- g is a single bond, J is CH2 and K is O, wherein CH2 is unsubstituted or substituted with R2.
- g is a single bond, J is a single bond, J is a single bond, J is
- g is a single bond
- J and K are CH2, wherein CH2 is unsubstituted or substituted with R2.
- g is a single bond
- g is a single bond
- J is
- g is a double bond
- J and K are selected from N and
- g is a double bond
- J and K are CH, wherein each CH is unsubstituted or substituted with R2.
- g is a double bond
- J and K are CH.
- L and M are each independently selected from the group consisting of: S, O, NH and CH2, wherein each NH is unsubstituted or substituted with Rg, and wherein each CH2 is unsubstituted or substituted with R2.
- M and L are each independently selected from the group consisting of: S, O, NH and CH2, wherein NH is unsubstituted or substituted with Rg, and wherein CH2 is unsubstituted or substituted with R2.
- M and L are each independently selected from the group consisting of: O, NH and CH2, wherein NH is unsubstituted or substituted with Rg, and wherein CH2 is unsubstituted or substituted with R2.
- g is a single bond
- M and L are CH2, wherein CH2 is unsubstituted or substituted with R2.
- g is a single bond
- T, U, V and W are each independently selected from N and CH, wherein CH is unsubstituted or substituted with R3.
- T, U, V and W are each CH, wherein CH is unsubstituted or substituted with R.3.
- T, U, V and W are each independently selected from N and CH, wherein CH is unsubstituted or substituted with R3, provided that at least one of T, U, V and W is N.
- T, U, V and W are each independently selected from N and CH, wherein CH is unsubstituted or substituted with R3, provided that one of T or W is N.
- T is N and U, V and W are CH, wherein CH is unsubstituted or substituted with R3.
- T, U, V are CH and W is N, wherein CH is unsubstituted or substituted with R3.
- X is CH2, wherein CH2 is unsubstituted or substituted with one or two substituents selected from R2. In a class of this embodiment of the present invention, X is CH2.
- Y is independently selected from the group consisting of: O, NH and CH2, wherein each NH is unsubstituted or substituted with Rg, and wherein each CH2 is unsubstituted or substituted with one or two substituents selected from R2.
- Y is CH2, wherein CH2 is unsubstituted or substituted with R2.
- Y is CH2.
- Z is independently selected from the group consisting of: S, S(O), S(O)2, O, NH and CH2, wherein each NH is unsubstituted or substituted with Rg, and wherein each CH2 is unsubstituted or substituted with R2.
- Z is independently selected from the group consisting of: S, O, NH and CH2, wherein each NH is unsubstituted or substituted with Rg, and wherein each CH2 is unsubstituted or substituted with R2.
- Z is independently selected from the group consisting of: O, NH and CH2, wherein each NH is unsubstituted or substituted with Rg, and wherein each CH2 is unsubstituted or substituted with R2.
- Z is independently selected from the group consisting of: O and CH2, wherein CH2 is unsubstituted or substituted with R2.
- Z is independently selected from the group consisting of: O and CH2-
- Z is CH2, wherein CH2 is unsubstituted or substituted with R2.
- X and Y are CH2 and Z is O, wherein each CH2 is unsubstituted or substituted with R2.
- X and Y are CH2 and Z is O.
- Y is CH2 and Z is O
- CH2 is unsubstituted or substituted with R2.
- Y is CH2 and Z is O.
- X is C-OH
- Y is CH2 and Z is O.
- X is CH-F
- Y is CH2 and Z is O.
- X is CH2, Y is -CH-CH3 and Z is O.
- X is CH2, Y is NH and Z is O, wherein NH is unsubstituted or substituted with Rg, and wherein CH2 is unsubstituted or substituted with R2.
- X and Z are CH2, and Y is NH, wherein NH is unsubstituted or substituted with Rg, and wherein each CH2 is unsubstituted or substituted with R2.
- Y is NH and Z is CH2, wherein NH is unsubstituted or substituted with Rg, and wherein CH2 is unsubstituted or substituted with R2.
- Y is NH and Z is CH2-
- Y is O
- X and Z are CH2, wherein each CH2 is unsubstituted or substituted with R2.
- Y is O and Z is CH2-
- X and Y are CH2and Z is S, wherein each CH2 is unsubstituted or substituted with R2.
- Y is CH2and Z is S, wherein each CH2 is unsubstituted or substituted with R2.
- Y is CH2 and Z is S.
- each Rl is independently selected from the group consisting of: hydrogen, halogen, and Ci .3 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents independently selected from halogen and hydroxy.
- each Rl is independently selected from the group consisting of: hydrogen, halogen, or C 1.3 alkyl.
- each Rl is hydrogen.
- each R2 is independently selected from the group consisting of: hydrogen, halogen, oxo, -Ci -6 alkyl, -OC ⁇ .6 alkyl, (CH2)nOR e , (CH 2 ) n N(Re)2, (CH 2 ) n C ⁇ N, (CH 2 ) n CORe, and (CH 2 ) n S(O) q Re, wherein alkyl is unsubstituted or substituted with hydroxy or one to three halogens; and wherein any CH2 in R2 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Cl .4 alkyl unsubstituted or substituted with one to five fluorines.
- each R2 is independently selected from the group consisting of: hydrogen, halogen, oxo, -C 1 -6 alkyl, -OC 1 -6 alkyl, (CH2) n OR e , (CH2) n N(R e )2, (CH2) n C ⁇ N, and (CH2)nC0R e , wherein alkyl is unsubstituted or substituted with hydroxy or one to three halogens; and wherein any CH2 in R2 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C 1.4 alkyl unsubstituted or substituted with one to five fluorines.
- each R2 is independently selected from the group consisting of: hydrogen, halogen, and oxo. In another subclass of this class, each R2 is independently selected from the group consisting of: hydrogen, bromo, chloro, fluoro, and oxo. In another subclass of this class, each R2 is independently selected from the group consisting of: hydrogen, and oxo. In another subclass of this class, each R2 is hydrogen. In another subclass of this class, each R2 is oxo.
- each R2 is independently selected from the group consisting of: hydrogen, deuterium, halogen, oxo, -Ci -6 alkyl, and -ORe, wherein alkyl is unsubstituted or substituted with hydroxy or one to three halogens.
- each R2 is independently selected from the group consisting of: hydrogen, deuterium, halogen, oxo, -Ci -6 alkyl, and -OH.
- each R2 is independently selected from the group consisting of: hydrogen, deuterium, fluoro, oxo, -CH3, and -OH.
- each R.3 is independently selected from the group consisting of: hydrogen, halogen, -Ci -6 alkyl, -Ci -6 alkenyl, -OCi -6 alkyl, and (CH2)nOR e , wherein alkyl is unsubstituted or substituted with one to three substituents selected from: hydroxy, halogen, C 1.4 alkyl, C3.6 cycloalkyl, C2-5 cycloheteroalkyl, aryl, and heteroaryl wherein alkyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are unsubstituted or substituted with one to three substituents selected from: halogen, hydroxy, and C 1.4 alkyl unsubstituted or substituted with one to five fluorines.
- each R3 is independently selected from the group consisting of: hydrogen, halogen, -Ci -6 alkyl, -Ci -6 alkenyl, -OCi -6 alkyl, and (CH2)nOR e , wherein alkyl is unsubstituted or substituted with one to three substituents selected from: hydroxy, halogen, Ci .4 alkyl, C3-6 cycloalkyl, and phenyl, wherein alkyl, cycloalkyl, and phenyl are unsubstituted or substituted with one to three substituents selected from: halogen, hydroxy, and Cl .4 alkyl unsubstituted or substituted with one to five fluorines.
- each R3 is independently selected from the group consisting of: hydrogen, halogen, -Ci -6 alkyl, -Ci- 6 alkenyl, -OCi -6 alkyl, and (CH2)nOR e , wherein alkyl is unsubstituted or substituted with one to three substituents selected from: hydroxy, halogen, Ci .4 alkyl, cyclopropyl and difluoro phenyl.
- each R3 is independently selected from the group consisting of: hydrogen, Cl, Br, -CH3, -CF3, and -OCF3. In a class of this embodiment, each R3 is independently selected from the group consisting of: Cl, Br, -CH3, - CF3, and -OCF3.
- R3 is independently selected from the group consisting of: hydrogen, halogen, -C 1-6 alkyl, -OC 1-6 alkyl, (CH2) n 0R e , (CH2) n N(R e )2, (CH2) n C ⁇ N, (CH2) n CORe, and (CH2) n S(O) q Re, wherein alkyl is unsubstituted or substituted with hydroxy or one to three halogens; and wherein any CH2 in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C 1.4 alkyl unsubstituted or substituted with one to five fluorines.
- R3 is independently selected from the group consisting of: hydrogen, halogen, -C 1-6 alkyl, -OCi -6 alkyl, (CH2) n ORe, (CH2) n N(Re)2, (CH2) n C ⁇ N, and (CH2) n CORe, wherein alkyl is unsubstituted or substituted with hydroxy or one to three halogens; and wherein any CH2 in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C 1.4 alkyl unsubstituted or substituted with one to five fluorines.
- R3 is independently selected from the group consisting of: hydrogen, halogen, -Ci- 6 alkyl, -OH, and -OC 1-6 alkyl, wherein alkyl is unsubstituted or substituted with hydroxy or one to three halogens; and wherein any CH2 in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Cl .4 alkyl unsubstituted or substituted with one to five fluorines.
- R3 is independently selected from the group consisting of: hydrogen, halogen, -Ci -6 alkyl, -OH, and -OCi -6 alkyl.
- R3 is independently selected from the group consisting of: hydrogen, halogen, -OH, and -OCi -6 alkyl, wherein alkyl is unsubstituted or substituted with hydroxy or one to three halogens, and wherein any CH2 in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, -OH, and Ci .4 alkyl unsubstituted or substituted with one to five fluorines.
- R3 is independently selected from the group consisting of: hydrogen, halogen, -OH, and -OCi -6 alkyl.
- R3 is independently selected from the group consisting of: hydrogen, halogen, -OH and OCH3. In another subclass of this class, R3 is independently selected from the group consisting of: -OH and OCH3. In another subclass of this class, R3 is independently selected from the group consisting of: hydrogen, and halogen. In another subclass of this class, R3 is independently selected from the group consisting of: hydrogen, bromo, chloro and fluoro. In another subclass of this class, R3 is independently selected from the group consisting of: hydrogen, chloro and fluoro. In another subclass of this class, R3 is independently selected from the group consisting of: hydrogen, and chloro. In another subclass of this class, R3 is chloro.
- R3 is halogen. In another subclass of this class, R3 is independently selected from the group consisting of: bromo, chloro and fluoro. In another subclass of this class, R3 is independently selected from the group consisting of: chloro and fluoro. In another class of this embodiment, R3 is chloro.
- R3 is independently selected from the group consisting of: hydrogen, halogen, -Ci -6 alkyl, -OCi -6 alkyl, (CH2) n 0Re, (CH2) n N(Re)2, (CH2) n C ⁇ N, and (CH2)nCORe, wherein alkyl is unsubstituted or substituted with hydroxy or one to three halogens; and wherein any CH2 in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Cl .4 alkyl unsubstituted or substituted with one to five fluorines.
- R3 is independently selected from the group consisting of: hydrogen, halogen, -C 1-6 alkyl, -OH, and -OC 1-6 alkyl, wherein alkyl is unsubstituted or substituted with hydroxy or one to three halogens; and wherein any CH2 in R3 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C 1-4 alkyl unsubstituted or substituted with one to five fluorines.
- R4 is selected from the group consisting of: heteroaryl, and cycloheteroalkyl, wherein any NH group is unsubstituted or substituted with RC, and wherein any CH or CH 2 group is unsubstituted or substituted with 1 to 2 substituents selected from Rd.
- R4 is heteroaryl, wherein any NH group is unsubstituted or substituted with R c , and wherein any CH or CH 2 group is unsubstituted or substituted with one substituent selected from Rd.
- R4 is heteroaryl, wherein any NH group is unsubstituted or substituted with R c , and wherein any CH group is unsubstituted or substituted with one substituent selected from Rd.
- R4 is cycloheteroalkyl, wherein any NH group is unsubstituted or substituted with R c , and wherein any CH or CH 2 group is unsubstituted or substituted with one substituent selected from Rd.
- R4 is cycloheteroalkyl, wherein any NH group is unsubstituted or substituted with Rc, and wherein any CH 2 group is unsubstituted or substituted with one to two substituents selected from Rd.
- R4 is selected from the group consisting of:
- R4 is selected from the group consisting of:
- R4 is selected from the group consisting of:
- R4 is selected from the group consisting of:
- R4 is selected from the group consisting of:
- N A
- R4 is:
- R4 is selected from the group consisting of:
- R4 is:
- each R a is independently selected from the group consisting of: hydrogen, halogen, cyano, C 1.4 alkyl, unsubstituted or substituted with one to five fluorines, C 1-4 alkoxy, unsubstituted or substituted with one to five fluorines, C 1.4 alkylthio, unsubstituted or substituted with one to five fluorines, Cl .4 alkylsulfonyl, -CO2H, Q. 4 alkyloxycarbonyl, and Cl .4 alkylcarbonyl.
- R a is independently selected from the group consisting of: hydrogen, halogen, cyano, and C 1.4 alkyl, unsubstituted or substituted with one to five fluorines.
- R a is independently selected from the group consisting of: hydrogen, and Cl .4 alkyl, unsubstituted or substituted with one to five fluorines.
- Ra is hydrogen.
- R a is Ci .4 alkyl, unsubstituted or substituted with one to five fluorines.
- R a is C 1.4 alkyl.
- each Rb is independently selected from the group consisting of: hydrogen, and Cl .4 alkyl, wherein alkyl is unsubstituted or substituted with one to five fluorines.
- Rb is hydrogen.
- Rb is C 1-4 alkyl, wherein alkyl is unsubstituted or substituted with one to five fluorines.
- Rb is Cl .4 alkyl.
- each Rc is independently selected from the group consisting of: -(CH2) m C ⁇ 2H, -(CH2) m C ⁇ 2Ci_3 alkyl, -(CH2) m -NRb-(CH2) p C ⁇ 2H, -(CH2)m-NRb-(CH2) p C ⁇ 2Ci-3 alkyl, -(CH 2 ) m -O-(CH2)pC ⁇ 2H, -(CH2)m-O-(CH2) p CO 2 Ci. 3 alkyl, -(CH2) m -S-(CH2) p C ⁇ 2H, and -(CH2) m -S-(CH2) p C ⁇ 2Ci-3 alkyl, wherein any CH2 in
- R c is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Ci .4 alkyl unsubstituted or substituted with one to five fluorines.
- Rc is selected from the group consisting of: -(CH2)mCO2H, - (CH2) m CO 2 Ci-3 alkyl, -(CH 2 ) m OCOH, -(CH 2 ) m OCOCi-3 alkyl, -(CH 2 ) m COH, - (CH2) m COCi_3 alkyl, -(CH2)m-NRb-(CH 2 )pCO 2 H, -(CH 2 )m-NRb-(CH2)pC ⁇ 2Ci- 3 alkyl, - (CH2) m -O-(CH2)pC ⁇ 2H, and -(CH2) m -O-(CH2) p C ⁇ 2Ci-3 alkyl, wherein any CH2 in
- Rc is selected from the group consisting of: -(CH2)mCO2H, - (CH 2 ) m C ⁇ 2Ci-3 alkyl, -(CH 2 ) m OCOH, -(CH 2 ) m OCOCi-3 alkyl, -(CH2) m COH, and -
- Rc is selected from the group consisting of: -(CH2) m C ⁇ 2H, -(CH2) m C ⁇ 2Ci-3 alkyl, -(CH2) m OCOH, - (CH 2 )mOCOCi-3 alkyl, -(CH 2 ) m COH, -(CH 2 ) m COCi.
- Rc is selected from the group consisting of: -(CH2)mCO2H, and -(CH2)mCO2Ci-3 alkyl, wherein any CH2 in R c is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C 1.4 alkyl unsubstituted or substituted with one to five fluorines.
- R c is -(CH2)mCO2H.
- R c is -(CH2)mCO2Ci-3 alkyl.
- each Rd is independently selected from the group consisting of: -(CH2) n C ⁇ 2H, -(CH2) n C ⁇ 2Ci_3 alkyl, -(CH2) n -NRb-(CH2) p CC>2H, - (CH2)n-NRb-(CH 2 )pC ⁇ 2Cl-3 alkyl, -(CH2) n -O-(CH 2 ) p C ⁇ 2H, -(CH2)n-O-(CH 2 )pC ⁇ 2Ci-3 alkyl, -(CH2) n -S-(CH2) p C ⁇ 2H, and -(CH2) n -S-(CH2) p C ⁇ 2Ci-3 alkyl, wherein any CH2 in Rd is unsubstituted or substituted with one to two groups independently selected from the group consisting of: halogen, hydroxy, and C] .4 alkyl unsubstituted or substituted with one
- each Rd is independently selected from the group consisting of: -(CH 2 ) n C ⁇ 2H, -(CH 2 )nC ⁇ 2Ci-3 alkyl, -(CH2) n -NRb-(CH2) p CO 2 H, -(CH 2 ) n - NRb-(CH2)pC02Ci_3 alkyl, -(CH2) n -O-(CH2)pCO 2 H, and -(CH2)n-O-(CH2)pCO 2 Ci-3 alkyl, wherein any CH2 in Rd is unsubstituted or substituted with one to two groups independently selected from the group consisting of: halogen, hydroxy, and Cl .4 alkyl unsubstituted or substituted with one to five fluorines.
- Rd is selected from the group consisting of: -(CH2) n C ⁇ 2H, -(CH2) n C ⁇ 2Ci_3 alkyl, -(CH2) n -NRb-(CH2) p C ⁇ 2H, and -(CH2)n-NRb-(CH2)pCO2Ci-3 alkyl, wherein any CH2 in Rd is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and Cl .4 alkyl unsubstituted or substituted with one to five fluorines.
- Rd is selected from the group consisting of: -(CH2) n C ⁇ 2H, and -(CH2) n -NRb-(CH2)pC ⁇ 2H, wherein any CH2 in Rd is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C 1.4 alkyl unsubstituted or substituted with one to five fluorines.
- Rd is selected from the group consisting of: -CH2CO2H, and - NH-CH2CO2H.
- Rd is -CH2CO2H.
- Rd is -NH-CH2CO2H.
- each R e is independently selected from the group consisting of: hydrogen, and Cl -6 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents independently selected from the group consisting of halogen, cyano, -Ci .4 alkoxy, -Ci .4 alkylthio, -Ci .4 alkylsulfonyl, -CO2H, and -CO2C1.4 alkyl.
- R e is hydrogen.
- Re is C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents independently selected from the group consisting of: halogen, cyano, -C 1.4 alkoxy, -C 1.4 alkylthio, -Ci .4 alkylsulfonyl, -CO2H, and -CO2C1-4 alkyl.
- Re is C 1-6 alkyl.
- each Rg is independently selected from the group consisting of: hydrogen, and Ci -6 alkyl.
- Rg is hydrogen.
- Rg is Cl -6 alkyl.
- g is a single bond or a double bond.
- g is a single bond.
- g is a double bond.
- m is 1, 2, or 3.
- s is 1 or 2.
- m is 2 or 3.
- m is 1 or 3.
- m is 1.
- m is 2.
- m is 3.
- n is 0, 1, 2 or 3. In a class of this embodiment, n is 0, 1 or 2. In another class of this embodiment, n is 0 or 1. In another class of this embodiment, n is 1 or 2. In another class of this embodiment, n is 0 or 2. In another class of this embodiment, n is 0. In another class of this embodiment, n is 1. In another class of this embodiment, n is 2. In another class of this embodiment, n is 3.
- p is 1, 2, or 3. In a class of this embodiment, p is 1 or 2. In another class of this embodiment, p is 2 or 3. In another class of this embodiment, p is 1 or 3. In another class of this embodiment, p is 1. In another class of this embodiment, p is 2. In another class of this embodiment, p is 3.
- q is 1 or 2. In another class of this embodiment, q is 1. In another class of this embodiment, q is 2.
- r is 0, 1, 2 or 3. In a class of this embodiment, r is 0, 1 or 2. In another class of this embodiment, r is 0 or 1. In another class of this embodiment, r is 1 or 2. In another class of this embodiment, r is 0 or 2. In another class of this embodiment, r is 0. In another class of this embodiment, r is 1. In another class of this embodiment, r is 2. In another class of this embodiment, r is 3.
- s is 0, 1, 2, 3 or 4. In a class of this embodiment, s is 0, 1, 2 or 3. In a class of this embodiment, s is 0, 1 or 2. In another class of this embodiment, s is 0 or 1. In another class of this embodiment, s is 1 or 2. In another class of this embodiment, s is 0 or 2. In another class of this embodiment, s is 0. In another class of this embodiment, s is 1. In another class of this embodiment, s is 2. In another class of this embodiment, s is 3. In another embodiment of the present invention, t is 0, 1, 2, 3, 4, 5, 6, 7 or 8. In a class of this embodiment, t is 0, 1, 2, 3 or 4. In a class of this embodiment, t is 0, 1, 2 or 3.
- t is 0, 1 or 2. In another class of this embodiment, t is 0 or 1. In another class of this embodiment, t is 1 or 2. In another class of this embodiment, t is 0 or 2. In another class of this embodiment, t is 0. In another class of this embodiment, t is 1. In another class of this embodiment, t is 2. hi another class of this embodiment, t is 3. In another class of this embodiment, t is 4. In another class of this embodiment, t is 5. In another class of this embodiment, t is 6. In another class of this embodiment, t is 7. In another class of this embodiment, t is 8. In another embodiment of the present invention, d is 0, 1 or 2. In a class of this embodiment, d is 0. In another class of this embodiment, d is 1. In another class of this embodiment, d is 2.
- e is 0, 1 or 2. In a class of this embodiment, e is 0. In another class of this embodiment, e is 1. In another class of this embodiment, e is 2.
- d is 0, and e is 2. In another embodiment of the present invention, d is 1 and e is 1. In another embodiment of the present invention, d is 2 and e is 0.
- the invention relates to compounds of structural formula I, wherein: A is selected from the group consisting of:
- B is selected from the group consisting of:
- R2 is independently selected from the group consisting of: hydrogen, deuterium, halogen, oxo, - C 1-6 alkyl, and -ORe, wherein alkyl is unsubstituted or substituted with hydroxy or one to three halogens; each IIS is independently selected from the group consisting of: hydrogen, halogen, -Ci_6 alkyl, - C i_6 alkenyl, -OCi -6 alkyl, and -(CH2)nOR e , wherein alkyl is unsubstituted or substituted with one to three substituents selected from: hydroxy, halogen, C 1.4 alkyl, C3.6 cycloalkyl, C2-5 cycloheteroalkyl, aryl, and heteroaryl wherein alkyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are unsubstituted or substituted with one to three substituents selected from: halogen
- the invention relates to compounds of structural formula I, wherein: A is selected from the group consisting of:
- B is selected from the group consisting of:
- R4 i is R3 is independently selected from the group consisting of: hydrogen, halogen and -OCH3; and s is 0 or 1 ; or a pharmaceutically acceptable salt thereof.
- the invention relates to compounds of structural formula I, wherein:
- A is:
- B- R4 is selected from the group consisting of:
- each R.3 is independently selected from the group consisting of: Cl, Br, -CH3, -CF3, and -OCF3;
- R4 is:
- s is 1 ; or a pharmaceutically acceptable salt thereof.
- the invention relates to compounds of structural formula Ia:
- the invention relates to compounds of structural formula Ib:
- the invention relates to compounds of structural formula Ic:
- the invention relates to compounds of structural formula Id:
- the invention relates to compounds of structural formula Ie:
- the invention relates to compounds of structural formula If:
- the invention relates to compounds of structural formula Ig:
- the invention relates to compounds of structural formula Ih:
- the invention relates to compounds of structural formula Ii:
- the invention relates to compounds of structural formula Ij :
- Alkyl as well as other groups having the prefix “alk”, such as alkoxy and alkanoyl, means carbon chains which may be linear or branched, and combinations thereof, unless the carbon chain is defined otherwise.
- alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and the like. When no number of carbon atoms is specified, C 1-6 is intended.
- alkenyl shall mean straight or branched-chain alkenes having the specified number of carbon atoms. Examples of alkenyl include vinyl, 1-propenyl, 1-butenyl, 2-butenyl, and the like.
- alkynyl refers to straight or branched-chain alkynes having the specified number of carbon atoms. Examples of alkynyl include ethynyl, propynyl, butynyl, pentynyl, and the like.
- alkoxy refers to straight or branched chain alkoxides of the number of carbon atoms specified (e.g., C ⁇ . ⁇ alkoxy), or any number within this range [i.e., methoxy
- alkylthio refers to straight or branched chain alkylsulfides of the number of carbon atoms specified (e.g., C 1-6 alkylthio), or any number within this range [i.e., methylthio (MeS-), ethylthio, isopropylthio, etc.].
- alkylsulfonyl refers to straight or branched chain alkylsulfones of the number of carbon atoms specified (e.g., Ci -6 alkylsulfonyl), or any number within this range [i.e., methylsulfonyl (MeSO2-), ethylsulfonyl, isopropylsulfonyl, etc.].
- alkyloxycarbonyl refers to straight or branched chain esters of a carboxylic acid derivative of the present invention of the number of carbon atoms specified (e.g., Cl -6 alkyloxycarbonyl), or any number within this range [i.e., methyloxycarbonyl (MeOCO-), ethyloxycarbonyl, or butyloxycarbonyl].
- Aryl means a mono- or polycyclic aromatic ring system containing carbon ring atoms.
- the preferred aryls are monocyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls. The most preferred aryl is phenyl.
- Cycloalkyl means a saturated carbocyclic ring having a specified number of carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. A cycloalkyl group generally is monocyclic unless stated otherwise. Cycloalkyl groups are saturated unless otherwise defined. “Cycloheteroalkyl” means nonaromatic, mono- or bicyclic or bridged saturated carbocyclic rings, each having from 2 to 14 carbon atoms and containing 1, 2, 3, 4 or 5 heteroatoms selected from N, NH, O and S.
- cycloheteroalkyl examples include tetrahydrofuranyl, azetidinyl, perhydroazepinyl, dihydrofuranyl, dioxanyl, oxanyl, morpholinyl, 1 ,4-dithianyl, piperazinyl, piperidinyl, 1,3-dioxolanyl, imidazolidinyl, imidazolinyl, pyrrolinyl, pyrrolidinyl, pyranyl, tetrahydropyranyl, dihydropyranyl, oxathiolanyl, dithiolanyl, 1,3-dithianyl, oxathianyl, thiomorpholinyl, dioxidoisothiazolidinyl, azacycloheptyl, diazobicyclo [3.2.1] -octane, and hexahydroindazolyl.
- the cycloheteroalkyl ring may be substituted on the ring carbons and/or the ring nitrogens.
- cycloheteroalkyl is substituted or unsubstituted piperazine.
- Heteroaryl means an aromatic or partially aromatic heterocycle that contains at least one ring heteroatom selected from O, S and N. Heteroaryls thus includes heteroaryls fused to other kinds of rings, such as aryls, cycloalkyls and heterocycles that are not aromatic.
- heteroaryl groups include: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl (in particular, l,3,4-oxadiazol-2-yl and l,2,4-oxadiazol-3-yl), thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, triazinyl, thienyl, pyrimidyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzofuranyl, indolinyl, pyridazinyl, indazolyl, isoindolyl, dihydrobenzothienyl, indolizinyl, cinnolinyl, phthalazinyl, quinazolinyl, naphth
- 5 membered heteroaryl ring means an aromatic or partially aromatic heterocycle that contains at least one ring heteroatom selected from O, S and N.
- 5 membered heteroaryl rings include: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl (in particular, l,3,4-oxadiazol-2-yl and l,2,4-oxadiazol-3-yl), thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, triazinyl, thienyl, and the like.
- Halogen refers to fluorine, chlorine, bromine and iodine. Chlorine and fluorine are generally preferred. Fluorine is most preferred when the halogens are substituted on an alkyl or alkoxy group (e.g. CF3O and CF3CH2O).
- compounds of structural formula I includes the compounds of structural formula I, Ia, Ib, Ic, Id, Ie, If, Ig, Ih and Ii, and pharmaceutically acceptable salts thereof.
- Compounds of structural formula I may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of structural formula I.
- Compounds of structural formula I may be separated into their individual diastereoisomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof, or via chiral chromatography using an optically active stationary phase.
- Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.
- any stereoisomer of a compound of the general structural formula I may be obtained by stereo specific synthesis using optically pure starting materials or reagents of known absolute configuration.
- racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated.
- the separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.
- the coupling reaction is often the formation of salts using an enantiomerically pure acid or base.
- the diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue.
- the racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art.
- Some of the compounds described herein may exist as tautomers, which have different points of attachment of hydrogen accompanied by one or more double bond shifts.
- a ketone and its enol form are keto-enol tautomers.
- the individual tautomers as well as mixtures thereof are encompassed with compounds of the present invention.
- the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominately found in nature.
- the present invention is meant to include all suitable isotopic variations of the compounds of structural formula I.
- isotopic forms of hydrogen include protium ( 1 H) and deuterium ( 2 H).
- Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
- Isotopically-enriched compounds within structural formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
- references to the compounds of structural formula I are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or their pharmaceutically acceptable salts or in other synthetic manipulations.
- the compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts of basic compounds encompassed within the term “pharmaceutically acceptable salt” refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
- Representative salts of basic compounds of the present invention include, but are not limited to, the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate),
- suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, and basic ion-exchange resins, such as arginine, betaine, caffeine, choline, N 5 N- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
- basic ion-exchange resins such as arginine, betaine, caffeine, choline, N 5 N- di
- esters of carboxylic acid derivatives such as methyl, ethyl, or pivaloyloxymethyl
- acyl derivatives of alcohols such as acetyl, pivaloyl, benzoyl, and aminoacyl
- esters and acyl groups known in the art for modifying the solubility or hydrolysis characteristics for use as sustained-release or prodrug formulations.
- Solvates, in particular hydrates, of the compounds of structural formula I are included in the present invention as well.
- the subject compounds are useful in a method of inhibiting the stearoyl-coenzyme A delta-9 desaturase enzyme (SCD) in a patient such as a mammal in need of such inhibition comprising the administration of an effective amount of the compound.
- SCD stearoyl-coenzyme A delta-9 desaturase enzyme
- the compounds of the present invention are therefore useful to control, prevent, and/or treat conditions and diseases mediated by high or abnormal SCD enzyme activity.
- a condition or disease mediated by high or abnormal SCD enzyme activity is defined as any disease or condition in which the activity of SCD is elevated and/or where inhibition of SCD can be demonstrated to bring about symptomatic improvements for the individual so treated.
- a condition or disease mediated by high or abnormal SCD enzyme activity includes, but is not limited to cardiovascular disease, dyslipidemias, (including but not limiting to disorders of serum levels of triglycerides, hypertriglyceridemia, VLDL, HDL, LDL, cholesterol, and total cholesterol, hypercholesterolemia, as well as cholesterol disorders), familial combined hyperlipidemia, coronary artery disease, atherosclerosis, heart disease, cerebrovascular disease (including but not limited to stroke, ischemic stroke, and transient ischemic attack), peripheral vascular disease, and ischemic retinopathy.
- dyslipidemias including but not limiting to disorders of serum levels of triglycerides, hypertriglyceridemia, VLDL, HDL, LDL, cholesterol, and total cholesterol, hypercholesterolemia, as well as cholesterol disorders
- familial combined hyperlipidemia including but not limited to stroke, ischemic stroke, and transient ischemic attack
- peripheral vascular disease including but not limited to stroke, ischemic stroke, and transient ische
- a condition or disease mediated by high or abnormal SCD enzyme activity also includes metabolic syndrome (including but not limited to dyslipidemia, obesity and insulin resistance, hypertension, microalbuminemia, hyperuricaemia, and hypercoagulability), Syndrome X, diabetes, insulin resistance, decreased glucose tolerance, non-insulin-dependent diabetes mellitus, Type II diabetes, Type I diabetes, diabetic complications, body weight disorders
- metabolic syndrome including but not limited to dyslipidemia, obesity and insulin resistance, hypertension, microalbuminemia, hyperuricaemia, and hypercoagulability
- Syndrome X diabetes, insulin resistance, decreased glucose tolerance, non-insulin-dependent diabetes mellitus, Type II diabetes, Type I diabetes, diabetic complications, body weight disorders
- a condition or disease mediated by high or abnormal SCD enzyme activity also includes fatty liver, hepatic steatosis, hepatitis, non-alcoholic hepatitis, non-alcoholic steatohepatitis, alcoholic hepatitis, acute fatty liver, fatty liver of pregnancy, drug-induced hepatitis, erythrohepatic protporphyria, iron overload disorders, hereditary hemochromatosis, hepatic fibrosis, hepatic cirrhosis, hepatoma and conditions related thereto.
- one aspect of the present invention concerns a method of treating hyperglycemia, diabetes or insulin resistance in a mammalian patient in need of such treatment, which comprises administering to said patient an effective amount of a compound in accordance with structural formula I or a pharmaceutically salt or solvate thereof.
- a second aspect of the present invention concerns a method of treating non-insulin dependent diabetes mellitus (Type 2 diabetes) in a mammalian patient in need of such treatment comprising administering to the patient an antidiabetic effective amount of a compound in accordance with structural formula I.
- a third aspect of the present invention concerns a method of treating obesity in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with structural formula I in an amount that is effective to treat obesity.
- a fourth aspect of the invention concerns a method of treating metabolic syndrome and its sequelae in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with structural formula I in an amount that is effective to treat metabolic syndrome and its sequelae.
- the sequelae of the metabolic syndrome include hypertension, elevated blood glucose levels, high triglycerides, and low levels of HDL cholesterol.
- a fifth aspect of the invention concerns a method of treating a lipid disorder selected from the group consisting of dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with structural formula I in an amount that is effective to treat said lipid disorder.
- a sixth aspect of the invention concerns a method of treating atherosclerosis in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with structural formula I in an amount effective to treat atherosclerosis.
- a seventh aspect of the invention concerns a method of treating cancer in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with structural formula I in an amount effective to treat cancer.
- a further aspect of the invention concerns a method of treating a condition selected from the group consisting of (1) hyperglycemia, (2) low glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16) neurodegenerative disease, (17) retinopathy, (18) nephropathy, (19) neuropathy, (20) fatty liver disease, (21) polycystic ovary syndrome, (22) sleep-disordered breathing, (23) metabolic syndrome, and (24) other conditions and disorders where insulin resistance is a component, in a mammalian patient in need of such treatment comprising administering to the patient a compound in accordance with structural formula I in an amount that is effective to treat said condition.
- Yet a further aspect of the invention concerns a method of delaying the onset of a condition selected from the group consisting of (1) hyperglycemia, (2) low glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16) neurodegenerative disease, (17) retinopathy, (18) nephropathy, (19) neuropathy, (20) fatty liver disease, (21) polycystic ovary syndrome, (22) sleep-disordered breathing, (23) metabolic syndrome, and (24) other conditions and disorders where insulin resistance is a component, and other conditions and disorders where insulin resistance is a component, in a mammalian patient in need of such treatment comprising administering to the patient a compound in accordance with structural formula I in an
- Yet a further aspect of the invention concerns a method of reducing the risk of developing a condition selected from the group consisting of (1) hyperglycemia, (2) low glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16) neurodegenerative disease, (17) retinopathy, (18) nephropathy, (19) neuropathy, (20) fatty liver disease, (21) polycystic ovary syndrome, (22) sleep-disordered breathing, (23) metabolic syndrome, and (24) other conditions and disorders where insulin resistance is a component, in a mammalian patient in need of such treatment comprising administering to the patient a compound in accordance with structural formula I in an amount that is effective to reduce the risk of developing said condition.
- mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent, such as a mouse, species can be treated.
- the method can also be practiced in other species, such as avian species (e.g., chickens).
- the present invention is further directed to a method for the manufacture of a medicament for inhibiting stearoyl-coenzyme A delta-9 desaturase enzyme activity in humans and animals comprising combining a compound of the present invention with a pharmaceutically acceptable carrier or diluent.
- the present invention is directed to the use of a compound of structural formula I in the manufacture of a medicament for use in treating a condition selected from the group consisting of hyperglycemia, Type 2 diabetes, insulin resistance, obesity, and a lipid disorder in a mammal, wherein the lipid disorder is selected from the group consisting of dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, and high LDL.
- the subject treated in the present methods is generally a mammal, preferably a human being, male or female, in whom inhibition of stearoyl-coenzyme A delta-9 desaturase enzyme activity is desired.
- therapeutically effective amount means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
- composition as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- Such term in relation to pharmaceutical composition is intended to encompass a product comprising the active ingredient(s) and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
- the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- administering a should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to the individual in need of treatment.
- SCD stearoyl-coenzyme A delta-9 desaturase
- the potency of compounds of formula I against the stearoyl-Co A desaturase was determined by measuring the conversion of radiolabeled stearoyl-Co A to oleoyl-CoA using rat liver microsome or human SCDl following previously published procedures with some modifications (Joshi, et al., J. Lipid Res., 18: 32-36 (1977); Talamo, et al., Anal. Biochem, 29: 300-304 (1969)). Liver microsome was prepared from male Wistar or Spraque Dawley rats on a high carbohydrate diet for 3 days (LabDiet # 5803, Purina).
- the livers were homogenized (1 :10 w/v) in a buffer containing 250 raM sucrose, 1 mM EDTA, 5 mM DTT and 50 mM Tris-HCl (pH 7.5). After a 100,000 x g centrifugation for 60 min, the liver microsome pellet was suspended in a buffer containing 100 mM sodium phosphate, 20% glycerol, 2 mM DTT, and stored at -78 0 C.
- Human SCDl desaturase system was reconstituted using human SCDl from a baculovirus/Sf9 expression system, cytochrome B5 and cytochrome B5 reductase.
- test compound in 2 ⁇ L DMSO was incubated for 15 min at room temperature with 180 ⁇ L of the SCD enzyme in a buffer containing 100 mM Tris-HCl (pH 7.5), ATP (5 mM), Coenzyme-A (0.1 mM), Triton X-100 (0.5 mM) and NADH (2 mM).
- reaction mixture 80 ⁇ L was mixed with a calcium chloride/charcoal aqueous suspension (100 ⁇ L charcoal (10% w/v) plus 25 ⁇ L CaCl 2 (2N). After centrifugation to precipitate the radioactive fatty acid species, tritiated water released from 9,10-[ 3 H]-stearoyl-CoA by the SCD enzyme was quantified on a scintillation counter.
- Human HepG2 cells were grown on 24-well plates in MEM media (Gibco cat# 11095- 072) supplemented with 10% heat-inactivated fetal bovine serum at 37 0 C under 5% CO 2 in a humidified incubator. Test compound dissolved in the media was incubated with the subconfluent cells for 15 min at 37 0 C. [l- 14 C]-stearic acid was added to each well to a final concentration of 0.05 ⁇ Ci/mL to detect SCD-catalyzed [ 14 C]-oleic acid formation.
- the labeled cellular lipids were hydro lyzed under nitrogen at 65 0 C for 1 h using 400 ⁇ L of 2N sodium hydroxide plus 50 ⁇ L of L- ⁇ -phosphatidylcholine (2 mg/mL in isopropanol, Sigma #P-3556). After acidification with phosphoric acid (60 ⁇ L), the radioactive species were extracted with 300 ⁇ L of acetonitrile and quantified on a HPLC that was equipped with a C- 18 reverse phase column and a Packard Flow Scintillation Analyzer.
- the compounds of the present invention including the compounds of Examples 1 to 81, exhibit an SCD inhibition constant IC50 of less than 1 ⁇ M.
- Preferred compounds of the present invention were found to exhibit an SCD inhibition constant IC50 of less than 0.1 ⁇ M.
- the in vivo efficacy of compounds of formula I was determined by following the conversion of [l- 14 C]-stearic acid to [1- 14 C]oleic acid in animals as exemplified below. Mice were dosed with a compound of formula I and one hour later the radioactive tracer, [1- 14 C]- stearic acid, was dosed at 20 ⁇ Ci/kg IV. At 3 h post dosing of the compound, the liver was harvested and then hydrolyzed in 10 N sodium hydroxide for 24 h at 80 0 C, to obtain the total liver fatty acid pool.
- the subject compounds are further useful in a method for the prevention or treatment of the aforementioned diseases, disorders and conditions in combination with other agents.
- the compounds of the present invention may be used in combination with one or more other drugs in the treatment, prevention, suppression or amelioration of diseases or conditions for which compounds of Formula I or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone.
- Such other drug(s) may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of Formula I.
- a pharmaceutical composition in unit dosage form containing such other drugs and the compound of Formula I is preferred.
- the combination therapy may also include therapies in which the compound of formula I and one or more other drugs are administered on different overlapping schedules.
- the compounds of the present invention and the other active ingredients may be used in lower doses than when each is used singly.
- the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of Formula I.
- the compounds of the present invention may be used in combination with one or more other drugs in the treatment, prevention, suppression or amelioration of diseases or conditions for which compounds of Formula I or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone.
- Such other drug(s) may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of Formula I.
- a pharmaceutical composition in unit dosage form containing such other drugs and the compound of Formula I is preferred.
- the combination therapy may also include therapies in which the compound of formula I and one or more other drugs are administered on different overlapping schedules.
- the compounds of the present invention and the other active ingredients may be used in lower doses than when each is used singly.
- the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of Formula I. Examples of other active ingredients that may be administered in combination with a compound of formula I, and either administered separately or in the same pharmaceutical composition, include, but are not limited to:
- DPP-4 dipeptidyl peptidase-IV
- insulin sensitizers including (i) PPAR ⁇ agonists, such as the glitazones (e.g. troglitazone, pioglitazone, englitazone, MCC-555, rosiglitazone, balaglitazone, and the like) and other PPAR ligands, including PPAR ⁇ / ⁇ dual agonists, such as KRP-297, muraglitazar, naveglitazar, Galida, TAK-559, PP ARa agonists, such as fenofibric acid derivatives (gemfibrozil, clof ⁇ brate, fenofibrate and bezaf ⁇ brate), and selective PPAR ⁇ modulators (SPPAR ⁇ M's), such as disclosed in WO 02/060388, WO 02/08188, WO 2004/019869, WO 2004/020409, WO 2004/
- sulfonylureas and other insulin secretagogues such as tolbutamide, glyburide, glipizide, glimepiride, and meglitinides, such as nateglinide and repaglinide;
- ⁇ -glucosidase inhibitors such as acarbose and miglitol
- glucagon receptor antagonists such as those disclosed in WO 98/04528, WO 99/01423, WO 00/39088, and WO 00/69810;
- GLP-I GLP-I, GLP-I analogues or mimetics, and GLP-I receptor agonists, such as exendin-4 (exenatide), liraglutide (NN-2211), CJC-1131, LY-307161, and those disclosed in WO 00/42026 and WO 00/59887;
- GIP and GIP mimetics such as those disclosed in WO 00/58360, and GIP receptor agonists;
- PACAP PACAP, PACAP mimetics, and PACAP receptor agonists such as those disclosed in WO 01/23420;
- cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, cerivastatin, fluvastatin, atorvastatin, itavastatin, and rosuvastatin, and other statins), (ii) sequestrants (cholestyramine, colestipol, and dialkylaminoalkyl derivatives of a cross-linked dextran), (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PP ARa agonists such as fenofibric acid derivatives (gemfibrozil, clof ⁇ brate, fenofibrate and bezafibrate), (v) PPAR ⁇ / ⁇ dual agonists, such as naveglitazar and muraglitazar, (vi) inhibitors of cholesterol absorption, such as beta-sitosterol and ezetimibe, (vii) HMG
- agents intended for use in inflammatory conditions such as aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, azulfidine, and selective cyclooxygenase-2 (COX-2) inhibitors;
- NSAIDs non-steroidal anti-inflammatory drugs
- COX-2 selective cyclooxygenase-2
- antihypertensive agents such as ACE inhibitors (enalapril, lisinopril, captopril, quinapril, tandolapril), A-II receptor blockers (losartan, candesartan, irbesartan, valsartan, telmisartan, and eprosartan), beta blockers and calcium channel blockers;
- ACE inhibitors enalapril, lisinopril, captopril, quinapril, tandolapril
- A-II receptor blockers leartan, candesartan, irbesartan, valsartan, telmisartan, and eprosartan
- beta blockers and calcium channel blockers
- GKAs glucokinase activators
- Dipeptidyl peptidase-IV inhibitors that can be combined with compounds of structural formula I include those disclosed in US Patent No. 6,699,871; WO 02/076450 (3 October 2002); WO 03/004498 (16 January 2003); WO 03/004496 (16 January 2003); EP 1 258 476 (20 November 2002); WO 02/083128 (24 October 2002); WO 02/062764 (15 August 2002); WO 03/000250 (3 January 2003); WO 03/002530 (9 January 2003); WO 03/002531 (9 January 2003); WO 03/002553 (9 January 2003); WO 03/002593 (9 January 2003); WO 03/000180 (3 January 2003); WO 03/082817 (9 October 2003); WO 03/000181 (3 January 2003); WO 04/007468 (22 January 2004); WO 04/032836 (24 April 2004); WO 04/037169 (6 May 2004); and WO 04/043940 (27 May 2004).
- DPP-IV inhibitor compounds include sitagliptin (MK-0431); vildagliptin (LAF 237); denagliptin; P93/01; saxagliptin (BMS 477118); RO0730699; MP513; SYR-322: ABT-279; PHXl 149; GRC-8200; and TS021.
- Antiobesity compounds that can be combined with compounds of structural formula I include fenfluramine, dexfenfluramine, phentermine, sibutramine, orlistat, neuropeptide Yi or Y5 antagonists, cannabinoid CBl receptor antagonists or inverse agonists, melanocortin receptor agonists, in particular, melanocortin-4 receptor agonists, ghrelin antagonists, bombesin receptor agonists, and melanin-concentrating hormone (MCH) receptor antagonists.
- MCH melanin-concentrating hormone
- Neuropeptide Y5 antagonists that can be combined with compounds of structural formula I include those disclosed in U.S. Patent No. 6,335,345 (1 January 2002) and WO 01/14376 (1 March 2001); and specific compounds identified as GW 59884A; GW 569180A; LY366377; and CGP-71683A.
- Cannabinoid CBl receptor antagonists that can be combined with compounds of formula I include those disclosed in PCT Publication WO 03/007887; U.S. Patent No. 5,624,941, such as rimonabant; PCT Publication WO 02/076949, such as SLV-319; U.S. Patent No.
- One particular aspect of combination therapy concerns a method of treating a condition selected from the group consisting of hypercholesterolemia, atherosclerosis, low HDL levels, high LDL levels, hyperlipidemia, hypertriglyceridemia, and dyslipidemia, in a mammalian patient in need of such treatment comprising administering to the patient a therapeutically effective amount of a compound of structural formula I and an HMG-CoA reductase inhibitor.
- this aspect of combination therapy concerns a method of treating a condition selected from the group consisting of hypercholesterolemia, atherosclerosis, low HDL levels, high LDL levels, hyperlipidemia, hypertriglyceridemia and dyslipidemia in a mammalian patient in need of such treatment
- the HMG-CoA reductase inhibitor is a statin selected from the group consisting of lovastatin, simvastatin, pravastatin, cerivastatin, fluvastatin, atorvastatin, and rosuvastatin.
- a method of reducing the risk of developing a condition selected from the group consisting of hypercholesterolemia, atherosclerosis, low HDL levels, high LDL levels, hyperlipidemia, hypertriglyceridemia and dyslipidemia, and the sequelae of such conditions comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of structural formula I and an HMG- CoA reductase inhibitor.
- a method for delaying the onset or reducing the risk of developing atherosclerosis in a human patient in need of such treatment comprising administering to said patient an effective amount of a compound of structural formula I and an HMG-CoA reductase inhibitor.
- the HMG-CoA reductase inhibitor is a statin selected from the group consisting of: lovastatin, simvastatin, pravastatin, cerivastatin, fluvastatin, atorvastatin, and rosuvastatin.
- a method for delaying the onset or reducing the risk of developing atherosclerosis in a human patient in need of such treatment is disclosed, wherein the HMG-Co A reductase inhibitor is a statin and further comprising administering a cholesterol absorption inhibitor.
- a method for delaying the onset or reducing the risk of developing atherosclerosis in a human patient in need of such treatment is disclosed, wherein the HMG-Co A reductase inhibitor is a statin and the cholesterol absorption inhibitor is ezetimibe.
- composition which comprises:
- DPP-IV dipeptidyl peptidase IV
- insulin sensitizers including (i) PPAR ⁇ agonists, such as the glitazones (e.g. troglitazone, pioglitazone, englitazone, MCC-555, rosiglitazone, balaglitazone, and the like) and other PPAR ligands, including PPAR ⁇ / ⁇ dual agonists, such as KRP-297, muraglitazar, naveglitazar, Galida, TAK-559, PP ARa agonists, such as fenofibric acid derivatives (gemfibrozil, clofibrate, fenofibrate and bezafibrate), and selective PPAR ⁇ modulators (SPPAR ⁇ M's), such as disclosed in WO 02/060388, WO 02/08188, WO 2004/019869, WO 2004/020409, WO 2004/020408, and WO 2004/066963; (ii) biguanides such as the
- sulfonylureas and other insulin secretagogues such as tolbutamide, glyburide, glipizide, glimepiride, and meglitinides, such as nateglinide and repaglinide;
- ⁇ -glucosidase inhibitors such as acarbose and miglitol
- glucagon receptor antagonists such as those disclosed in WO 98/04528, WO
- GLP-I, GLP-I analogues or mimetics, and GLP-I receptor agonists such as exendin-4 (exenatide), liraglutide (NN-2211), CJC-1131, LY-307161, and those disclosed in WO 00/42026 and WO 00/59887;
- GIP and GIP mimetics such as those disclosed in WO 00/58360, and GIP receptor agonists;
- PACAP PACAP, PACAP mimetics, and PACAP receptor agonists such as those disclosed in WO 01/23420;
- cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, cerivastatin, fluvastatin, atorvastatin, itavastatin, and rosuvastatin, and other statins), (ii) sequestrants (cholestyramine, colestipol, and dialkylaminoalkyl derivatives of a cross-linked dextran), (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PP ARa agonists such as fenofibric acid derivatives (gemfibrozil, clofibrate, fenofibrate and bezafibrate), (v) PPAR ⁇ / ⁇ dual agonists, such as naveglitazar and muraglitazar, (vi) inhibitors of cholesterol absorption, such as beta-sitosterol and ezetimibe, (vii) HMG
- PPAR ⁇ agonists such as those disclosed in WO 97/28149;
- antiobesity compounds such as fenfluramine, dexfenfluramine, phentermine, sibutramine, orlistat, neuropeptide Yi or Y5 antagonists, CBl receptor inverse agonists and antagonists, ⁇ 3 adrenergic receptor agonists, melanocortin-receptor agonists, in particular melanocortin-4 receptor agonists, ghrelin antagonists, bombesin receptor agonists (such as bombesin receptor subtype-3 agonists), and melanin-concentrating hormone (MCH) receptor antagonists;
- MCH melanin-concentrating hormone
- agents intended for use in inflammatory conditions such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, azulfidine, and selective cyclooxygenase-2 (COX-2) inhibitors;
- antihypertensive agents such as ACE inhibitors (enalapril, lisinopril, captopril, quinapril, tandolapril), A-II receptor blockers (losartan, candesartan, irbesartan, valsartan, telmisartan, and eprosartan), beta blockers and calcium channel blockers;
- GKAs glucokinase activators
- r inhibitors of cholesteryl ester transfer protein (CETP), such as torcetrapib;
- s inhibitors of fructose 1 ,6-bisphosphatase, such as those disclosed in U.S. Patent Nos. 6,054,587; 6,110,903; 6,284,748; 6,399,782; and 6,489,476;
- acetyl CoA carboxylase- 1 and/or -2 inhibitors (u) AMPK activators; and (v) agonists of GPR 119; and (3) a pharmaceutically acceptable carrier.
- a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred.
- the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of the present invention.
- the weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
- the weight ratio of the compound of the present invention to the other agent will generally range from about 1000:1 to about 1 :1000, preferably about 200:1 to about 1 :200.
- Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
- the compound of the present invention and other active agents may be administered separately or in conjunction.
- the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
- the compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
- parenteral e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant
- inhalation spray nasal, vaginal, rectal, sublingual, or topical routes of administration
- nasal, vaginal, rectal, sublingual, or topical routes of administration may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
- the compounds of the invention are effective for
- compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients.
- the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
- the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate.
- dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation
- the aqueous suspensions may also contain one or more preservatives, for example ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerin, glycerin, glycerin, glycerin, glycerin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol
- the pharmaceutical compositions of the invention may also be in the form of oil-in- water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally- occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3- butanediol.
- the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- the compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- Such materials are cocoa butter and polyethylene glycols.
- creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed.
- topical application shall include mouthwashes and gargles.
- the pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions.
- an appropriate dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses.
- the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day.
- a suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day.
- the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day.
- the compositions are preferably provided in the form of tablets containing 1.0 to 1000 mg of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0. 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
- the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
- the compounds of the present invention are administered at a daily dosage of from about 0.1 mg to about 100 mg per kilogram of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form.
- the total daily dosage is from about 1.0 mg to about 1000 mg, preferably from about 1 mg to about 50 mg. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 mg to about 350 mg. This dosage regimen may be adjusted to provide the optimal therapeutic response.
- the compounds of structural formula I can be prepared according to the procedures of the following Schemes and Examples, using appropriate materials and are further exemplified by the following specific example.
- the compound illustrated in the example is not, however, to be construed as forming the only genus that is considered as the invention.
- the Example further illustrates details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless otherwise noted.
- Mass spectra (MS) were measured by electrospray ion- mass spectroscopy (ESMS).
- ACN is acetonitrile
- Ac 2 O is acetic anhydride
- AcOH is acetic acid
- aq is aqueous
- Boc is tert-butyloxycarbonyl
- «-BuLi is r ⁇ -butyl lithium
- t-BuOH is tert-butanol
- t-BuLi is tert-butyl lithium
- t-BuONO is tert-butyl nitrite
- CAN is eerie ammonium nitrate
- CeliteTM is diatomaceous earth
- CuSO 4 is copper sulfate
- DAST is (diethylamino) sulfur trifluoride
- DBU is l,8-diazabicyclo-[5.4.0]undec-7-ene
- DCM is dichloromethane
- DEAD diethyl azodicarboxylate
- DIPEA or DIEA is jV, ⁇ V-diiso
- SiO 2 is silicon dioxide
- rt and RT is room temperature
- TEA is triethyl amine
- TFA is trifluoroacetic acid
- TFAA is trifluoroacetic anhydride
- THF is tetrahydrofuran
- TMP is 2,2,6,6-tetramethylpiperidine
- wt% is weight percent.
- the spiro moieties can be prepared according to the procedures described by L. Yang., et. al., Bioorg. Med. Chem. Lett., 8, 107-112 (1998). Here is an illustration with A-5.
- An appropriately substituted 2'-hydroxyacetophenone A-I is reacted with an appropriately substituted cyclic ketone intermediate A-2 in the presence of a base, such as pyrrolidine, in a solvent, such as methanol, to give the spiro-intermediate A-3.
- the carbonyl of intermediate A-3 is then reduced in a 2-step sequence via alcohol A-4 to give the spiro-cyclic amine intermediate A-5 for further coupling reaction.
- the spiro intermediate A-5 is either isolated as a free base or a salt with an acid such as HCl or TFA.
- R 3 OH in A-4, it can be further react with an alkyl or benzyl group to provide the corresponding alkylated analog.
- the functional group Y' is then converted by typical standard transformations to substituent R 4 to give the desired moiety for final product B-3.
- Other spiro moieties can be used to couple with B-2 to obtain the corresponding analogs.
- Step 2 tert-Butyl 5-chloro-4-oxo-3,4-dihvdro-l ⁇ -spiro[chromene-2,4'-piperidine1-r- carboxylate.
- a mixture of tert-butyl 4-oxopiperidine-l-carboxylate (14 g, 70.35 mmol, 1.00 equiv), pyrrolidine (7 g, 98.59 mmol, 1.40 equiv) and l-(2-chloro-6-hydroxyphenyl)ethanone (12 g, 70.59 mmol, 1.00 equiv) in MeOH (150 mL) was reacted at 65 0 C for 20 min.
- Step 3 tert-Butyl 5-chloro-4-hvdroxy-3,4-dihvdro-l ⁇ -spiro[chromene-2,4'-piperidinel-r- carboxylate.
- fert-butyl 5-chloro-4-oxo-3,4-dihydro-l'H-spiro[chromene-2,4'- piperidine]-l '-carboxylate (30 g, 85.27 mmol, 1.00 equiv) in EtOH (300 mL) was added portionwise NaBH 4 (3.3 g, 87.23 mmol, 1.02 equiv) at 25 0 C over 30 min.
- TFA salt was converted to the free base by the treatment with aqueous NaOH.
- the free base was then dissolved in Et 2 O and reacted with HCl gas to give the title compound as a white solid.
- Step 1 2-Bromo-l,3-thiazole-5-carboxamide
- ethyl 2- bromothiazole-5-carboxylate 50.0 g, 212 mmol
- THF 500 niL
- MeOH 250 mL
- concentrated ammonium hydroxide in water 590 mL
- the solvents were removed under reduced pressure, and the crude mixture poured into a separatory funnel containing brine (1 L).
- Step 2 2-Bromo-L3-thiazole-5-carbonitrile
- 2-bromo- l,3-thiazole-5-carboxamide 41.5 g, 201 mmol
- CH 2 Cl 2 1.3 L
- triethylamine 70 mL, 502 mmol
- the resulting solution was cooled to 0 °C and trifluoroacetic anhydride (34 mL, 241 mmol) was added slowly over 15 minutes.
- the reaction mixture was allowed to warm to room temperature and stirred for 2 h.
- the reaction mixture was poured into a 3 L separatory funnel containing saturated aqueous NaHCO 3 solution (500 mL).
- the aqueous layer was extracted with dichloromethane (2 x 1.2 L) and the combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
- the resulting crude reaction mixture was filtered through a short plug of silica gel on a sintered glass funnel, washing with copious quantities of EtOAc. The filtrate was concentrated under reduced pressure to provide the title compound.
- Step 3 5-(2-Bromo- 1 ,3-thiazol-5-yl)-2H-tetrazole
- 2-bromo-l,3-thiazole-5- carbonitrile 5.00 g, 26.5 mmol
- 2-propanol 75 mL
- water 38 mL
- ZnBr 2 5.96 g, 26.5 mmol
- sodium azide 2.58 g, 39.7 mmol
- the reaction mixture was heated at 120 °C for 5 h.
- Step 4 Ethyl r5-f2-bromo- 1.3-thiazol-5-yl)-2H-tetrazol-2-yllacetate
- 5-(2-bromo-l,3-thiazol-5-yl)-2//-tetrazole 5.43 g, 22.5 mmol
- T ⁇ F 81 mL
- triethylamine 7.2 mL, 52 mmol
- ethyl bromoacetate 3.8 mL, 34 mmol
- Step 1 Ethyl 5-bromo-l ,3,4-thiadiazole-2-carboxylate To a suspension of ethyl 5-amino-l,3,4- thiadiazole-2-carboxylate in CH 3 CN (0.32 M) was added CuBr 2 (2 equiv). The mixture turned dark green and was stirred for 15 min at room temperature. t-BuONO, 90% (2 equiv) was added dropwise over 15 - 20 min. The mixture became slightly warm and gas evolved after about 5 min and then throughout the addition. After completion of the addition and after gas evolution subsided, the mixture was heated at 60 °C for 30 min. Solvent was then evaporated in vacuo.
- Step 2 5-Bromo-l,3,4-thiadiazole-2-carboxamide
- THF 1.1 M
- concentrated NH 4 OH 2.9 equiv
- the mixture was stirred at room temperature overnight and a precipitate appeared in the aqueous layer. Volatile solvent was removed in vacuo.
- the mixture was diluted with water and the precipitate was collected, washed with water and dried under vacuum to give the title compound.
- lH NMR 400 MHz, acetone-J 6 ): ⁇ 7.99 (s, IH), 7.55 (s, IH).
- Step 3 5-Bromo- 1 ,3 ,4-thiadiazole-2-carbonitrile
- TFAA 1.1 equiv
- Step 1 Ethyl 3-bromo-4,5-dihydroisoxazole-5-carboxylate To a round-bottom flask containing hydroxycarbonimidic dibromide (100 g, 490 mmol) was slowly added DMF (300 mL) followed by ethyl acrylate (59 g, 590 mmol). The mixture was cooled to -10 0 C and then a solution of KHCO 3 (99 g, 990 mmol) in water (400 mL) was added dropwise over 90 min, at a rate which maintained the internal temperature below 0 0 C. Stirring was continued at 0 °C for 1.5 h.
- KHCO 3 99 g, 990 mmol
- Step 2 3-Bromo-4,5-dihydroisoxazole-5-carboxamide
- Ethyl 3-bromo-4,5-dihydroisoxazole-5- carboxylate (109 g, 490 mmol) was added to a 1 L round-bottom flask containing 2.0 M NH 3 in MeOH (295 mL).
- Step 3 3-Bromo-4,5-dihydroisoxazole-5-carbonitrile
- THF 360 mL
- triethylamine 43.0 mL, 311 mmol
- the solution was cooled to 0 0 C and TFAA (33.0 mL, 233 mmol) was added slowly over 20 min, at a rate which maintained the internal temperature below 15 0 C.
- the reaction mixture was stirred at 0 °C for 1 h.
- reaction mixture was poured into a 2 L separatory funnel containing water (500 mL) and the aqueous layer was extracted with MTBE (3 x 500 mL). The combined organic layers were washed with a saturated aqueous NaHCO 3 solution (2 x 250 mL) and brine, dried over MgSO 4 , filtered and concentrated under reduced pressure to afford the title compound.
- Step 4 5-(3-Bromo-4,5-dihvdroisoxazol-5-vD-2H-tetrazole
- 3-bromo-4,5- dihydroisoxazole-5-carbonitrile 39.4 g, 225 mmol
- zinc oxide 1.8 g, 23 mmol
- THF 40 mL
- water 200 mL
- Heating was applied at a rate in where the internal temperature of the reaction mixture did not exceed 80 °C.
- the reaction mixture was cooled to 0 °C and acidified to pH 3-4 with slow addition of 2 N aqueous HCl solution. During the acidification, the internal temperature was maintained below 5 °C.
- the reaction mixture was poured into a 2 L separately funnel and the aqueous layer was extracted with EtOAc (3 x 500 mL). The combined organic layers were washed with brine, dried over MgSO 4 , filtered and concentrated under reduced pressure to afford the title compound.
- Step 5 fert-Butyl [5-(3-bromo-4,5-dihvdroisoxazol-5-yl)-2H-tetrazol-2-yllacetate
- 5- (3-bromo-4,5-dihydroisoxazol-5-yl)-2//-tetrazole 49 g, 225 mmol
- THF 500 mL
- Triethylamine (53 mL, 383 mmol) was added to the mixture and the solution was heated to 55 °C while ter t-buty ⁇ bromoacetate (66 g, 338 mmol) was added. The mixture was heated at 55 °C for 1 h and then cooled to room temperature. The reaction mixture was poured into a 2 L separatory funnel containing 1 N aqueous HCl solution (500 mL) and the aqueous layer was extracted with EtOAc (3 x 500 mL). The combined organic layers were washed with brine, dried over MgSO 4 , filtered and concentrated under reduced pressure.
- Step 1 l-Bromo-2-(methoxymethoxy)-4-(trifluoromethoxy)benzene
- 2- bromo-5-(trifluoromethoxy)phenol 50 g, 195 mmol
- Hunig's base 120 mL, 687 mmol
- CH 2 Cl 2 100 mL
- MOM-Cl 35 mL, 461 mmol
- Step 2 l-r2-(Methoxymethoxy)-6-ftrifluoromethoxy)phenyl]ethanone
- a solution of l-bromo-2- (methoxymethoxy)-4-(trifluoromethoxy)benzene (60 g, 198 mmol) in THF (500 mL) at -100 °C was treated by a slow addition of t-BuLi in pentane (1.7M) (1.3 equiv) over 45 min by keeping internal temperature between -97 0 C to -102 °.
- Step 3 1 -
- a solution of l-[2- (methoxymethoxy)-6-(trifluoromethoxy)phenyl]ethanone (48 g, 181 mmol) in /-PrOH (60 mL) was added aq HCl 37% (8 mL, 97 mmol).
- the reaction mixture was heated to 50 0 C for 2 h, and then poured into water.
- the reaction mixture was cooled to 0 0 C, pentane was added (400 mL) and the mixture was poured into 0.5 N HCl (500 mL).
- Step 4 fer/-Butyl 4-oxo-5-(trifluoromethoxy)-3,4-dihvdro-r//-spiro[chromene-2,4'-piperidine]- 1 '-carboxylate
- a mixture of 75% in weight of l-[2-hydroxy-6- (trifluoromethoxy)phenyl]ethanone (50 g, 170 mmol), 1 -BOC-4-piperidone (32 g, 161 mmol) in xylene (50 mL) was treated with pyrrolidine (2.6 mL, 32.1 mmol). The mixture was heated to 105 0 C for 14 h by removing water and volatile solvents.
- the crude reaction was purified by column chromatography on SiO 2 (isocratic 100% hexanes and then a slow gradient from 5 to 20% EtOAc/hexanes). After evaporation of the solvents, the resulting material was triturated with hexanes at -78 °C. The cold suspension was filtered and trituration was repeated to afford the title compound as a white solid.
- Step 5 tert-Butyl 4-hvdroxy-5-(trifluoromethoxy)-3.,4-dihydro-rH-spiro[chromene-2,4'- piperidinel - 1 '-carboxylate
- a mixture of tert-butyl 4-oxo-5- (trifluoromethoxy)-3,4-dihydro-rH-spiro[chromene-2,4'-piperidine]-r-carboxylate 15 g, 37.4 mmol
- MeOH 50 mL
- NaBH 4 2.1 g, 56.1 mmol
- Step 6 5 -(Trifluoromethoxy)-3 ,4-dihvdrospiro f chromene-2,4'-piperidinium] chloride
- a cold (-78 °C) solution of tert-butyl 4-hydroxy-5-(trifluoromethoxy)-3,4-dihydro-rH- spiro[chromene-2,4'-piperidine]-r-carboxylate 15 g, 37.2 mmol) in CH 2 Cl 2 (80 mL) was treated with Et 3 SiH (24 mL, 150 mmol) followed by TFA (40 mL).
- the title compound may be synthesized according to the following procedure: To a solution of tert-butyl 4-hydroxy-5-(trifluoromethoxy)-3,4-dihydro-17/- spiro[chromene-2,4'-piperidine]-r-carboxylate (23.6 g, 58.5 mmol) in degassed EtOAc (234 mL) were added dropwise Pd(OH) 2 catalyst (4.72 g, 6.72 mmol) and MsOH (22.49 g, 234 mmol). The reaction was shaken on a Parr shaker under 50 psi of H 2 overnight.
- Step 2 l-[2-Bromo-6-(methoxymethoxy)phenyl]ethanone To a solution of diisopropylamine (9.85 mL, 69.1 mmol) in THF (100 mL) at -78 0 C was slowly added 2.5 M «-BuLi (29.9 mL, 74.9 mmol). The solution was warmed and stirred 20 min at 0 0 C, cooled to -100 °C before the slow addition of the cold THF (40 mL) solution of 1 -bromo-3 -(methoxymethoxy)benzene (12.5 g, 57.6 mmol) via a cannula.
- Step 3 l-(2-Bromo-6-hvdroxyphenyl)ethanone
- 2-propanol 100 mL
- aq HCl 37%, 20 mL, 244 mmol
- Step 4 tert-Butyl 5-bromo-4-oxo-3,4-dihvdro-rH-spiro[chromene-2,4'-piperidine1-r- carboxylate
- l-(2-bromo-6-hydroxyphenyl)ethanone (8.81 g, 41.0 mmol)
- l-boc-4- piperidone (8.82 g, 44.2 mmol)
- pyrrolidine 0.847 mL, 10.24 mmol
- Step 5 tert-Butyl 5-bromo-4-hvdroxy-3,4-dihvdro-r//-spiro[chromene-2,4'-piperidine]-r- carboxylate
- a mixture of tert-butyl 5-bromo-4-oxo-3,4-dihydro-rH-spiro[chromene-2,4'- piperidine]-l'-carboxylate (2.04 g, 5.15 mmol) in THF (20 mL) and MeOH (20 mL) was treated with NaBH 4 (0.390 g, 10.30 mmol) at 0 °C. The suspension was warmed to room temperature and stirred for 1 h.
- Step 6 5-Bromo-3,4-dihvdrospiro[chromene-2,4'-piperidinium] chloride
- a cold solution of tert- butyl 5-bromo-4-hydroxy-3,4-dihydro-rH-spiro[chromene-2,4'-piperidine]-r-carboxylate (514 mg, 1.291 mmol) in CH 2 Cl 2 (8 mL) was treated with triethylsilane (1.649 mL, 10.32 mmol), followed by TFA (4 mL). The final mixture was warmed to room temperature and then heated to 80 0 C for 5.5 h. The resulting mixture was concentrated under vacuum.
- Step 1 tert-Butyl 8-chloro-4-oxo-3,4-dihvdro-l ⁇ -spiro[chromene-2,4'-piperidine]-r- carboxylate
- l-(3-chloro-2-hydroxyphenyl)ethanone 500 mg, 2.93 mmol
- l-boc-4- piperidone 584 mg, 2.93 mmol
- pyrrolidine 61 ⁇ L, 0.738 mmol
- Step 2 fert-Butyl 8-chloro-4-hvdroxy-3,4-dihydro-r//-spiro[chromene-2,4'-piperidine1-r- carboxylate
- a mixture of tert-butyl 8-chloro-4-oxo-3,4-dihydro-l ⁇ -spiro[chromene-2,4'- piperidine]-l'-carboxylate (910 mg, 2.59 mmol) in THF (10 mL) and MeOH (10 mL) was treated with NaBH 4 (196 mg, 5.17 mmol) at 0 °C. The suspension was warmed to room temperature and stirred for 1 h.
- Step 3 8-Chloro-3,4-dihvdrospiro[chromene-2,4'-piperidinium] chloride
- TFA 10 mL
- tert-butyl 8-chloro-4-hydroxy-3,4-dihydro-rH-spiro[chromene-2,4'-piperidine]-r- carboxylate 905 mg, 2.56 mmol
- an exotherm was observed. Due to the exotherm, the solution was cooled rapidly to 0 0 C and it was treated with triethylsilane (1.634 mL, 10.23 mmol).
- the mixture was heated to 80 °C for 1.5 h.
- the resulting mixture was concentrated under vacuum.
- Step 1 tert-Butyl 5-iodo-4-oxo-3,4-dihvdro- 1 'H-spiro[chromene-2,4'-piperidine "
- Step 2 fert-Butyl 4-hydroxy-5-iodo-3,4-dihydro- 17/-spiro[chromene-2,4'-piperidinel- 1 '- carboxylate
- Step 3 5-Iodo-3,4-dihvdrospiro[chromene-2,4'-piperidinium] chloride
- a cold solution of tert- butyl 4-hydroxy-5-iodo-3,4-dihydro-r//-spiro[chromene-2,4'-piperidine]-r-carboxylate (800 mg, 1.797 mmol) in CH 2 Cl 2 (10 mL) was treated with triethylsilane (2.296 mL, 14.37 mmol) followed by TFA (5 mL). The final mixture was warmed to room temperature, then heated to 80 0 C for 10 h and concentrated under vacuum.
- Step 2 Ethyl ⁇ 5 - r2-(4-oxopiperidin- 1 -ylV 1 ,3 -thiazol-5-yll -2H-tetrazol-2-yl > acetate.
- Step 1 Ethyl JV- ⁇ [(2,2-dimethoxyethyl)aminolcarbonyl ⁇ glycinate To a solution of ethyl isocyanatoacetate (8.84 mL, 77 mmol) in CH 2 Cl 2 (100 mL) at 0 0 C was added aminoacetaldehyde dimethyl acetal (8.86 mL, 81 mmol) over a period of 10 min. The mixture was further stirred for 30 min, quenched with water. The CH 2 Cl 2 layer was separated, washed with water, dried (Na 2 SO 4 ) and concentrated to give the crude title compound as an oil.
- Step2 Ethyl (2-oxo-2,3 -dihydro- 1 H-imidazol- 1 -yl)acetate
- acetic acid 20 mL
- 80% aqueous formic acid 80 mL, 1669 mmol
- the mixture was stirred at 65 0 C for Ih. Most volatile materials were removed in vacuo.
- the residue was diluted with small amount of water (-10 to 20 mL) and extracted with EtOAc (3 x 50 mL).
- Step 1 5 -(5-Chloro-3 ,4-dihydro- 1 'H-spiro [chromene-2,4'-piperidin] - 1 '-vD- 1 ,3 ,4-thiadiazole-2- carbonitrile.
- 5-bromo-l,3,4-thiadiazole-2-carbonitrile 200 mg, 1.053 mmol
- Step 3 Ethyl ⁇ 5 - [5-(5 -chloro-3 ,4-dihydro- 1 'H-spiro
- Step 4 ⁇ 5-r5-(5-Chloro-3,4-dihvdro-l'H-spiro
- Step 1 Ethyl 3-bromo-4,5-dihvdroisoxazole-5-carboxylate.
- hydroxycarbonimidic dibromide (15.5 g, 76.4 mmol)
- ethyl acrylate (15.3 g, 153 mmol)
- DMF 200 mL
- a solution of 15 wt% aqueous KHCO 3 102 mL, 153 mmol.
- the mixture was stirred at room temperature overnight. Water was added and the mixture was extracted twice with methyl fert-butyl ether. The combined organic extracts were washed with brine, dried (Na 2 SO 4 ) and concentrated in vacuo to give the title compound.
- Step 2 3-Brorno-4,5-dihvdroisoxazole-5-carboxamide.
- a mixture of ethyl 3-bromo-4,5- dihydroisoxazole-5-carboxylate (6.2 g, 28 mmol) and a solution of 2 M ammonia in MeOH (56 mL) was stirred at room temperature for 1 to 2 hours. Volatile materials were removed in vacuo to give the crude title compound as a white solid.
- Step 3 3-(5-Chloro-3,4-dihvdro-rH-spiro[chromene-2,4'-piperidinl-r-yl)-4,5-dihydroisoxazole- 5-carboxamide.
- Step 4 3-(5-Chloro-3,4-dihydro-r//-spiro[chromene-2,4'-piperidin1-r-yl)isoxazole-5- carboxamide.
- 3-(5-chloro-3,4-dihydro-l'//-spiro[chromene-2,4'- piperidin]-r-yl)-4,5-dihydroisoxazole-5-carboxamide 420 mg, 1.2 mmol
- sodium acetate 295 mg, 3.6 mmol
- iodine 350 mg, 1.4 mmol
- Step 5 3-(5-Chloro-3,4-dihvdro-r//-spiro[chromene-2,4'-piperidinl-r-yl)isoxazole-5- carbonitrile.
- 3-(5-chloro-3,4-dihydro- 1 'H-spiro[chromene-2,4'-piperidin]- 1 '- yl)isoxazole-5-carboxamide 280 mg, 0.805 mmol
- TEA 0.337 mL, 2.415 mmol
- Step 6 f5-T3 -(5 -Chloro-3.4-dihydro- 1 'H-spiro rchromene-2,4'-piperidinl - 1 '-yl)isoxazol-5-yll -2H- tetrazol-2-yl ⁇ acetic acid
- the title compound was prepared in a similar manner as described for Example 1, Steps 2 to 4 starting from 3-(5-chloro-3,4-dihydro-l'H-spiro[chromene-2,4'- piperidinJ-r-y ⁇ isoxazole-S-carbonitrile.
- Step 1 tert-Butyl ⁇ 5- r2-(5-chloro-3 ,4-dihydro- 1 'H-spiro rchromene-2.4'-pi ⁇ eridin1 - 1 '-yl V 1.3- thiazol-5 -yl] -2H-tetrazol-2-yl ⁇ acetate.
- Step 2 ⁇ 5-r2-(5-Chloro-3.4-dihvdro-l'H-spirorchromene-2,4'-piperidinl-r-yl)-l,3-thiazol-5-yl1- 2H-tetrazol-2-yl ⁇ acetic acid.
- Step 1 fert-Butyl ( 5 - [2-(4-oxo-3 ,4-dihydro- 1 'H-spiro rchromene-2,4'-piperidinl - 1 '-yl> 1.3- thiazol-5-yll-2H-tetrazol-2-yl ⁇ acetate.
- Step 2 ⁇ 5- [2-(4-Oxo-3.4-dihvdro- 1 'H-spiro rchromene-2.4'-piperidinl - 1 '-vO- 1.3 -thiazol-5-vH - 2H-tetrazol-2-yl ⁇ acetic acid.
- Step 1 tert-Butyl ⁇ 5-r2-(2.3-dihydro- 1 'H-spiro [indene- 1 ,4'-piperidin1- 1 '-yl)-l .3-thiazol-5-yll- 2H-tetrazol-2-yl ⁇ acetate
- tert-butyl [5-(2-bromo-l,3-thiazol-5-yl)-2 ⁇ -tetrazol-2- yljacetate 80 mg, 0.231 mmol
- 2,3-dihydrospiro[indene-l,4'-piperidinium] chloride 69.8 mg, 0.312 mmol
- NMP 1.25 mL
- Step 2 ⁇ 5-r2-(2.3-Dihvdro-rH-spirorindene-l,4'-piperidinl-r-yl)-1.3-thiazol-5-yl1-2H-tetrazol- 2-yll acetic acid
- Water (0.4 mL) and formic acid (1.6 mL, 41.7 mmol) were added to tert-butyl ⁇ 5- [2-(2,3 -dihydro- 1 ⁇ -spiro [indene- 1 ,4'-piperidin] - 1 '-yl)- 1 ,3 -thiazol-5 -yl] -2 ⁇ -tetrazol-2- yl ⁇ acetate (43 mg, 0.095 mmol) and the solution was immersed into a preheated oil bath at 100 0 C for 1 h.
- Step 1 tert-Butv ⁇ ⁇ 5-r2- ⁇ 'H-spirori-benzofuran-3.4'-piperidin1-l'-yl)-13-thiazol-5-yll-2H- tetrazol-2-yl ⁇ acetate
- tert-butyl [5-(2-bromo-l,3-thiazol-5-yl)-2H-tetrazol-2- yljacetate 80 mg, 0.231 mmol
- spiro[l-benzofuran-3,4'-piperidine] 74.3 mg, 0.393 mmol
- NMP 1.25 mL
- DBU 70 ⁇ L, 0.464 mmol
- Step 2 ⁇ 5-[2-(l 'H-Spiro[ 1 -benzofuran-3,4'-piperidinl- 1 '-vD- 1.3-thiazol-5-yll-2/f-tetrazol-2- yl ⁇ acetic acid Water (0.4 mL) and formic acid (1.6 mL, 41.7 mmol) were added to tert-butyl ⁇ 5- [2-( 1 ⁇ -spiro [ 1 -benzofuran-3 ,4'-piperidin] - l'-yl)- 1 ,3 -thiazol-5-yl] -2H-tetrazol-2-yl ⁇ acetate (57 mg, 0.125 mmol) and the solution was immersed into a preheated oil bath at 100 0 C for 1 h.
- Step 2 ⁇ 5-r2-(l'H-Spirorindene-l,4'-piperidinl-r-yl)-1.3-thiazol-5-yll-2//-tetrazol-2-vU acetic acid
- Water (0.4 mL) and formic acid (1.6 mL, 41.7 mmol) were added to tert-butyl ⁇ 5-[2-(l'H- spiro[indene-l,4'-piperidin]-r-yl)-l,3-thiazol-5-yl]-2H-tetrazol-2-yl ⁇ acetate (61 mg, 0.135 mmol) and the solution was immersed into a preheated oil bath at 100 0 C for 1 h.
- Step 1 tert-Butyl I5-T5 -(4-oxo-3 ,4-dihvdro- 1 ⁇ -spiro
- the title compound was prepared in a similar manner as that described for Example 5 (step 1) from tert-butyl [5-(2-bromo-l,3-thiazol-5-yl)-2H- tetrazol-2-yl]acetate and spiro[chromene-2,4'-piperidin]-4(3 H )-one hydrochloride.
- Step 2 ⁇ 5 - [5-(4-Oxo-3 ,4-dihvdro- 1 ⁇ -spiro rchromene-2.4'-piperidinl - 1 '-ylV 1,3. 4-thiadiazol-2- yl]-2H-tetrazol-2-yl ⁇ acetic acid.
- Step 1 fert-Butyl ( 5 -r2-(4-oxo-3 ,4-dihvdro- 1 ⁇ -spiro [ 1 ,3 -benzoxazine-2.4'-piperidin1 - 1 '-v D-I, 3- thiazol-5 -yl] -2H-tetrazol-2-yl ⁇ acetate
- the title compound was prepared in a similar manner as that described for Example 5 (step 1) from tert-butyl [5-(2-bromo-l,3-thiazol-5-yl)-2H-tetrazol- 2-yl]acetate and spiro[l,3-benzoxazine-2,4'-piperidin]-4(3H)-one.
- Step 2 2-Methoxyethyl ⁇ [5-(5-chloro-3,4-dihydro-l' H -spiro[chromene-2,4'-piperidin]-l'- yl)[l,3 ]thiazolo[5,4- d ]pyrimidin-2-yl]amino ⁇ acetate
- the title compound was prepared from tert-butyl ⁇ 5 - [2-(4-oxo-3 ,4-dihydro- 1 ⁇ -spiro [ 1 ,3 -benzoxazine-2,4'-piperidin] - 1 '-yl)- 1 ,3 -thiazol- 5 -yl]-2H-tetrazol-2-yl ⁇ acetate and LiOH in THF-H 2 O at O 0 C.
- Step 1 tert-Butyl ⁇ 5-[5-(l-oxo-l,4-dihydro-l ⁇ -spiro[isochromene-3,4'-piperidin]-r-yl)-l,3,4- thiadiazol-2-yl]-2H-tetrazol-2-yl ⁇ acetate
- the title compound was prepared in a similar manner as that described for Example 5 (step 1) from tert-butyl [5-(2-bromo-l,3-thiazol-5-yi)-2H- tetrazol-2-yl] acetate and spiro [isochromene-3 ,4'-piperidin]-l(4H)-one hydrochloride.
- Step 2 ⁇ 5- ⁇ 5-( 1 -Oxo- 1 ,4-dihvdro- 1 ⁇ -spiro risochromene-3 ,4'-piperidinl - 1 '-yl)- 13 ,4-thiadiazol- 2-v ⁇ -2H-tetrazol-2-yl)acetic acid
- the title compound was prepared in a similar manner as that described for Example 8 (step 2) from fert-butyl ⁇ 5-[5-(l-oxo-l,4-dihydro-l'H- spiro [isochromene-3, 4'-piperidin]-l'-yl)-l, 3, 4-thiadiazol-2-yl]-2H-tetrazol-2-yl ⁇ acetate and TF A.
- Step 1 Benzyl 5-methoxy-4-oxo-3,4-dihydro-17/-spiro[chromene-2,4'-piperidine]-r- carboxylate.
- benzyl 4-oxopiperidine-l-carboxylate 2.354 g, 10.09 mmol
- methanol 21 ml
- freshly distilled pyrrolidine 1.2 ml, 14.51 mmol
- l-(2-hydroxy-6- methoxyphenyl)ethanone (1.92 g, 11.55 mmol) was added and the mixture stirred under external temperature of +73 0 C for 90 min, cooled down to room temperature, diluted with EtOAc and successively washed with aqueous 5% KHSO 4 , 2M NaOH in water and water, dried over MgSO 4 , filtered and concentrated.
- Step 2 Benzyl-4-hvdroxy-5-methoxy-3,4-dihydro-rH-spiro[chromene-2,4'-piperidine1-r- carboxylate.
- Step 3 5-methoxy-3,4-dihvdrospirorchromene-2,4'-piperidine]
- a degassed solution of benzyl4- hydroxy-5-methoxy-3,4-dihydro- 1 'H-spiro[chromene-2,4'-piperidine]- 1 '-carboxylate (576 mg, 1.502 mmol) in ethyl acetate (25 ml) was treated with solid 10% Pd on carbon (223 mg, 14 mol%), and then MeOH (150 ml) was added. After stirring under vacuum for 3 min, a balloon filled with H 2 was adapted and the final suspension stirred at room temperature for 6 h.
- Step 4 Ethyl (5-r5-(5-methoxy-3.4-dihvdro-rH-spirorchromene-2.4'-piperidin1-r-yl)-l,3,4- thiadiazol-2-yl]-2H-tetrazol-2-yl I acetate.
- Step 5 ⁇ 5- [5 -(5-Methoxy-3 ,4-dihydro- 1 'H-spiro rchromene-2,4'-piperidin1 - 1 '-v ⁇ - 1.3.4- thiadiazol-2-yl]-2//-tetrazol-2-yl ⁇ acetic acid.
- Step 1 Ethyl ⁇ 5-[5 -(5-chloro-4-oxo-3.4-dihydro- 177-spiro rchromene-2,4'-piperidin1 - 1 '-vD- 1.3,4- thiadiazol-2-vH -2H-tetrazol-2-yl ) acetate.
- Intermediate 5 100 mg, 0.313 mmol
- 5-chlorospiro[chromene-2,4'-piperidin]-4(3//)-one hydrochloride 99 mg, 0.345 mmol
- THF 1.6 mL
- TEA 131 ⁇ l, 0.94 mmol
- Step 2 ( 5- 1 ⁇ 5 -(5 -Chloro-4-oxo-3 ,4-dihydro- 1 'H-spiro rchromene-2.4'-piperidin
- Step 1 tert-Butyl ⁇ 5- [2-(5 -chloro-4-oxo-3.4-dihydro- 1 'H-spiro rchromene-2,4'-piperidin1 - 1 '-vO- l,3-thiazol-5-yll-27/-tetrazol-2-vU acetate.
- the title compound was prepared in a similar manner as that described for Example 5 Step 1 from Intermediate 3 and 5-chlorospiro[chromene-2,4'- piperidin]-4(3//)-one hydrochloride.
- Step 2 ⁇ 5-r2-(5-Chloro-4-oxo-3,4-dihydro-l'//-spirorchromene-2.4'-piperidinl-l'-yl)-1.3- thiazol-5-yl "
- the title compound was prepared in a similar manner as that described for Example 9 Step 2 from tert-butyl ⁇ 5-[2-(5-chloro-4-oxo-3,4-dihydro-17/- spiro[chromene-2,4'-piperidin]-r-yl)-l,3-thiazol-5-yl]-2H-tetrazol-2-yl ⁇ acetate and LiOH at 0 0 C.
- Step 1 tert-Butyl ⁇ 5 - [3 -(5-chloro-4-oxo-3 ,4-dihvdro- 1 'H-spiro rchromene-2,4'-piperidinl - 1 '-vD- 4,5-dihydroisoxazol-5-yll-2H-tetrazol-2-yl ⁇ acetate.
- Step 2 tert-ButvU5-[3-(5-chloro-4-oxo-3,4-dihvdro-l 'H-spiro
- Step 3 ( 5 -[3 -(5 -Chloro-4-oxo-3 ,4-dihvdro- 1 'H-spiro [chromene-2,4'-piperidin] - 1 '-yl)isoxazol-5- yl]-2H-tetrazol-2-yl)acetic acid
- the title compound was prepared in a similar manner as that described for Example 8 Step 2 from tert-butyl ⁇ 5-[3-(5-chloro-4-oxo-3,4-dihydro-l'H- spiro[chromene-2,4'-piperidin]-l'-yl)isoxazol-5-yl]-2H-tetrazol-2-yl ⁇ acetate and TFA.
- Step 1 tert-Butyl (5-I3-F5 -(trifluoromethoxy)-3 ,4-dihydro- 1 '//-spiro
- a suspension of dried Na 2 CO 3 (694 mg, 6.55 mmol) in anhydrous t-BuOH was added 5-(trifluoromethoxy)-3,4- dihydrospiro[chromene-2,4'-piperidinium] chloride (848 mg, 2.62 mmol) (Intermediate 8) and tert-buty ⁇ [5-(3-bromo-4,5-dihydroisoxazol-5-yl)-2//-tetrazol-2-yl]acetate (725 mg, 2.183 mmol) (Intermediate 7).
- Step 2 tert-Butyl (5- ⁇ 3-r5-(trifluoromethoxy)-3,4-dihvdro-r//-spiro[chromene-2,4'-piperidin]- r-yl]isoxazol-5-yl ⁇ -2//-tetrazol-2-yl)acetate
- tert-butyl (5- ⁇ 3-[5-(trifluoromethoxy)-3,4- dihydro-r//-spiro[chromene-2,4'-piperidin]-r-yl]-4,5-dihydroisoxazol-5-yl ⁇ -2H-tetrazol-2- yl)acetate (880 mg, 1.634 mmol) in THF (10 mL) was added in one portion CAN (1344 mg, 2.451 mmol) at -78°C.
- Step 3 (5- ⁇ 3 - F5 -(Trifluoromethoxy)-3 ,4-dihydro- 1 '//-spiro [chromene-2,4'-piperidin] - 1 '- yl]isoxazol-5-yl
- Water (0.8 mL) and formic acid (3.2 mL, 83 mmol) were added to tert-butyl (5- ⁇ 3-[5-(trifluoromethoxy)-3,4-dihydro-17/-spiro[chromene- 2,4'-piperidin]-l'-yl]isoxazol-5-yl ⁇ -2//-tetrazol-2-yl)acetate (378 mg, 0.705 mmol) and the final solution was immersed into a preheated oil bath at 100 0 C for 30 min.
- Step 1 tert-Butyl (5- ⁇ 5-[5-(trifluoromethoxy)-3,4-dihvdro-r//-spiro[chromene-2,4'-piperidinl- 1 '-yll - 1 ,3 ,4-thiadiazol-2-yl ) -2//-tetrazol-2-yl)acetate
- a solution of tert-butyl [5-(5-bromo- 1,3,4- thiadiazol-2-yl)-2H-tetrazol-2-yl]acetate (10.5 g, 30.2 mmol; Intermediate 6) and 5- (trifluoromethoxy)-3,4-dihydrospiro[chromene-2,4'-piperidinium] chloride (10.77 g, 33.3 mmol; Intermediate 8) in THF (30 mL) was treated with Hunig's base (15.85 mL, 91 mmol).
- Step 2 (5- ⁇ 5- r5-(Trifluoromethoxy)-3 ,4-dihydro- 1 '//-spiro rchromene-2,4'-piperidinl - 1 '-yll - 1 ,3 ,4- thiadiazol-2-yl ) -2//-tetrazol-2-yl)acetic acid
- Water 13 mL
- formic acid 52 mL, 1356 mmol
- tert-buty ⁇ (5- ⁇ 5-[5-(trifluoromethoxy)-3,4-dihydro-l'//-spiro[chromene- 2,4'-piperidin]-l'-yl]-l,3,4-thiadiazol-2-yl ⁇ -2//-tetrazol-2-yl)acetate (12.0 g, 21.68 mmol) and the final suspension was heated to 100 0 C for 30 min.
- Step 1 fert-Butyl (5- ⁇ 2-
- Step 2 (5- (2- r5-(Trifluoromethoxy)-3 ,4-dihydro- 1 '//-spiro rchromene-2,4'-piperidinl - l'-yl] - 1 ,3 - thiazol-5-vU-2//-tetrazol-2-yl)acetic acid Water (7.6 mL) and formic acid (30 mL, 782 mmol) were added to fert-butyl (5- ⁇ 2-[5-(trifluoromethoxy)-3,4-dihydro-17/-spiro[chromene-2,4'- piperidin]-r-yl]-l,3-thiazol-5-yl ⁇ -2H-tetrazol-2-yl)acetate (7.80 g, 14.1 mmol) and the final solution was heated to 100 0 C for 2 h.
- Step 1 fert-Butyl (5- ⁇ 2-[4-oxo-5-(trifluoromethoxy)-3,4-dihvdro-l ⁇ -spiro[chromene-2,4'- piperidin] - 1 '-yl] - 1 ,3 -thiazol-5 -yl ⁇ -2H-tetrazol-2-yl)acetate
- ter/-butyl [5-(2- bromo-l,3-thiazol-5-yl)-2H-tetrazol-2-yl]acetate (308 mg, 0.888 mmol)
- 4- oxo-5-(trifluoromethoxy)-3,4-dihydrospiro[chromene-2,4'-piperidinium] chloride 250 mg, 0.740 mmol; Intermediate 9) in NMP (1 mL) was added DBU (0.223 mL, 1.48 mmol).
- Step 2 (5- ⁇ 2-[4-Oxo-5-(trifluoromethoxy)-3 ,4-dihydro- 1 'H-spiro[chromene-2,4'-piperidinl-l '- yll-l,3-thiazol-5-yl ⁇ -2H-tetrazol-2-yl)acetic acid Water (0.4 mL) and formic acid (1.6 mL, 41.7 mmol) were added to tert-butyl (5- ⁇ 2-[4-oxo-5-(trifluoromethoxy)-3,4-dihydro-r//- spiro[chromene-2,4'-piperidin]-l'-yl]-l,3-thiazol-5-yl ⁇ -2H-tetrazol-2-yl)acetate (328 mg, 0.579 mmol) and the final solution was immersed into a preheated oil bath at 100 0 C for 45 min.
- Step 1 fert-Butyl 5-methyl-4-oxo-3,4-dihydro-rH-spiro[chromene-2,4'-piperidine1-r- carboxylate.
- tert-buty ⁇ 5- bromo-4-oxo-3,4-dihydro-l' -spiro[chromene-2,4'-piperidine]-r-carboxylate 50.0 mg, 0.13 mmol; Intermediate 10, Step 4
- potassium methyltrifluoroborate 14 mg, 0.12 mmol
- PdCl 2 (dppf)-C ⁇ 2 Cl 2 (9.38 mg, 0.011 mmol)
- cesium carbonate (112 mg, 0.34 mmol).
- the reaction mixture was stirred at reflux for 16h in a sealed tube.
- the volatiles were evaporated under reduced pressure.
- the resulting residue was diluted with water (10 mL)/lN HCl (10 mL) and extracted with DCM (3 x 5 mL) using a separation cartridge.
- the residue was purified by CombiflashTM chromatography (SiO 2 , 12 g, elution with 0-60% EtOAc/hexanes over 40 min) to afford the title compound as an oil.
- Step 2 5 -Methylspiro [chromene-2,4'-piperidinl -4(3H)-one.
- tert-Butyl 5-methyl-4-oxo-3,4- dihydro-r//-spiro[chromene-2,4'-piperidine]-r-carboxylate 25 mg, 0.08 mmol was diluted in 4N HCl in dioxane (3 mL) and placed in a round bottom flask equipped with a condenser. The mixture was heated periodically (every 10 min) to reflux using a heat gun for a total of 30 min. Then the volatiles were evaporated under reduced pressure to afford the title compound as a solid.
- Step 3 fert-ButvU5-[2-(5-methyl-4-oxo-3,4-dihvdro-r/J-spiro[chromene-2,4'-piperidinl-r -yl)- l,3-thiazol-5-yll-2//-tetrazol-2-vUacetate.
- the title compound was prepared in a similar manner as that described for Example 5 (step 1) from 5-methylspiro[chromene-2,4'-piperidin]-4(3H)-one and Intermediate 3.
- Step 4 ⁇ 5- F2-(5 -Methyl-4-oxo-3 ,4-dihvdro- 1 'H-spiro [chromene-2,4'-piperidinl - 1 '-ylV 1,3- thiazol-5-yl]-2H-tetrazol-2-yl
- Step 1 fert-Butyl ⁇ 5 - [3 -(5-methyl-4-oxo-3 , 4-dihvdro- 1 'H-spiro rchromene-2.4'-piperidin1 - 1 '-vD- 4,5-dihydroisoxazol-5-yl "
- the title compound was prepared in a similar manner as that described for Example 15 (step 1) from 5-methylspiro[chromene-2,4'- piperidin]-4(3H)-one and Intermediate 3.
- Step 2 ferf-Butyl ⁇ 5 - [3 -(5-methyl-4-oxo-3 ,4-dihydro- 1 'H-spiro [chromene-2,4'-piperidin] - 1 '- yl)isoxazol-5-yl "
- Step 3 ⁇ 5-[3-(5-Methyl-4-oxo-3,4-dihvdro-rH-spiro[chromene-2,4'-piperidinl-r-yl)isoxazol-5- yl]-2H-tetrazol-2-vU acetic acid.
- the title compound was prepared in a similar manner as that described for Example 9 (step 2) from ter/-butyl ⁇ 5-[3-(5-methyl-4-oxo-3,4-dihydro-l'H- spiro[chromene-2,4'-piperidin]-r-yl)isoxazol-5-yl]-2H-tetrazol-2-yl ⁇ acetate and LiOH.
- Step 1 fert-Butyl (5-[5-(5-vinyl-3.4-dihvdro-l'H-spirorchromene-2.4'-piperidin1-r-yl)-l, 3,4- thiadiazol-2-yll-2//-tetrazol-2-vU acetate.
- the reaction mixture was diluted with EtOAc (5mL)/water (10 mL) and then acidified with IN HCl (10 mL). The organic layer was extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with water (10 mL), brine (10 mL), dried OnMgSO 4 , filtered and evaporated under reduced pressure. The residue was purified by CombiflashTM chromatography (SiO 2 , 12 g, elution with 0-40% EtOAc/hexanes over 40 min) to afford the title compound as solid.
- Step 2 ⁇ 5-r5-(5-Vinyl-3,4-dihvdro-rH-spirorchromene-2,4'-piperidinl-r-vn-l,3,4-thiadiazol-2- yll-2H " -tetrazol-2-vU acetic acid
- the title compound was prepared in a similar manner as that described for Example 9 (step 2) from tert-butyl ⁇ 5-[5-(5-vinyl-3,4-dihydro-17/-spiro[chromene- 2,4'-piperidin]-r-yl)-l, 3, 4-thiadiazol-2-yl]-2H-tetrazol-2-yl ⁇ acetate and LiOH.
- Step 1 fert-ButvU5-r5-(5-ethyl-3,4-dihvdro-l'H-spirorchromene-2.4'-piperidinl-l'-yl)-l,3,4- thiadiazol-2-yll -2H-tetrazol-2-yl I acetate.
- Step 2 ⁇ 5-r5-(5-Ethyl-3,4-dihvdro-l'//-spirorchromene-2,4'-piperidinl-r-yl)-l,3,4-thiadiazol-2- yl]-2//-tetrazol-2-vU acetic acid.
- the title compound was prepared in a similar manner as that described for Example 8 (step 2) from /er/-butyl ⁇ 5-[5-(5-ethyl-3,4-dihydro-rH-spiro[chromene- 2,4'-piperidin]-l'-yl)-l, 3 ,4-thiadiazol-2-yl]-2H-tetrazol-2-yl ⁇ acetate and TFA.
- Step 1 8-Bromo-5-fluorospirorchromene-2,4'-piperidinl-4(3//)-one hydrochloride
- the title compound was prepared in a similar manner as that described for Intermediate 1 (steps 1 and 2) and follow by the procedure detail in Example 36 (step 2), starting from 2-bromo-5- fluorophenol.
- Step 2 ⁇ 5 - r2-(8-Bromo-5-fluoro-4-oxo-3 ,4-dihydro- 1 'H-spiro rchromene-2,4'-piperidin] - 1 '-vD-
- Step 1 tert-Butyl ⁇ 5- ⁇ 2-( 1 -oxo- 1 ,4-dihydro- 177-spiro
- the title compound was prepared in a similar manner as that described for Example 5 (step 1) from Intermediate 3 and spiro[isochromene-3,4'-piperidin]- 1 (4H)-one hydrochloride.
- Step 2 ⁇ 5- ⁇ 2-( 1 -Oxo- 1 ,4-dihydro- 1 'H-spirorisochromene-3 ,4'-pi ⁇ eridinl - 1 '-yl> 1.3 -thiazol-5-yll - 2//-tetrazol-2-yU acetic acid.
- Step 1 tert-Butyl (5-[2-(8-chloro-l -oxo- 1 ,4-dihydro- 1 'H-spiro [isochromene-3,4'-piperidin
- the title compound was prepared in a similar manner as that described for Example 5 (step 1) from Intermediate 3 and Intermediate 16.
- Step 2 ⁇ 5- r2-(8-Chloro- 1 -oxo- 1.4-dihvdro- 1 'H-spiro risochromene-3 ,4'-piperidin1 - 1 '-yl)- 1,3- thiazol-S-yll ⁇ H-tetrazol ⁇ -yljacetic acid.
- Step 1 fert-Butyl ⁇ 5-[5-(8-chloro- 1 -oxo- 1 ,4-dihydro- 1 'H-spiro [isochromene-3 ,4'-piperidin "
- the title compound was prepared in a similar manner as that described for Example 13 (step 1) from Intermediate 6 and Intermediate 16.
- Step 2 ⁇ 5- [2-(8-Chloro-l -oxo- 1 ,4-dihydro- 1 'H-spiro [isochromene-3, 4'-piperidin1-l '-yl)-l ,3- thiazol-5-yll-2H-tetrazol-2-yl
- Step 1 tert-Butyl ⁇ 5- [3 -(8-chloro- 1 -oxo- 1 ,4-dihydro- 1 'H-spiro [isochromene-3 ,4'-piperidin] - 1 '- yl)-4,5-dihydroisoxazol-5-yl]-2H-tetrazol-2-yUacetate.
- the title compound was prepared in a similar manner as that described for Example 15 (step 1) from Intermediate 7 and Intermediate 16.
- Step 2 tgrt-ButvUS-P-fS-chloro-l-oxo-l ⁇ -dihvdro-rH-spirofisochromene-S ⁇ '-piperidinl-r- yl)isoxazol-5-yll-2H-tetrazol-2-yl
- acetate tgrt-ButvUS-P-fS-chloro-l-oxo-l ⁇ -dihvdro-rH-spirofisochromene-S ⁇ '-piperidinl-r- yl)isoxazol-5-yll-2H-tetrazol-2-yl
- acetate tgrt-ButvUS-P-fS-chloro-l-oxo-l ⁇ -dihvdro-rH-spirofisochromene-S ⁇ '-piperidinl-r- yl)isoxazol-5-yll-2H-t
- the title compound was prepared in a similar manner as that described for Example 15 (step 2) from fert-butyl ⁇ 5-[3-(8-chloro-l-oxo-l,4-dihydro-l'H- spiro [isochromene-3 ,4'-piperidin]- 1 '-yl)-4,5-dihydroisoxazol-5-yl]-2H-tetrazol-2-yl ⁇ acetate and CAN.
- Step 3 ⁇ 5 - [3 -(8-Chloro- 1 -oxo- 1 ,4-dihydro- 1 'H-spiro [isochromene-3 ,4'-piperidinl - 1 '- yl)isoxazol-5-yl "
- the title compound was prepared in a similar manner as that described for Example 8 (step 2) from tert-Butyl ⁇ 5-[3-(8-chloro-l-oxo-l,4- dihydro-rH-spiro[isochromene-3,4'-piperidin]-l'-yl)isoxazol-5-yl]-2H-tetrazol-2-yl ⁇ acetate and TFA.
- Step 2 2-Hydroxy-6-(trifluoromethyl)benzamide.
- 2-fluoro-6- (trifluoromethyl)benzamide 500 mg, 2.41 mmol
- diglyme 8.05 mL
- potassium trimethylsilanolate 1.08 g, 8.45 mmol
- the reaction mixture was stirred at 120 0 C overnight.
- the reaction mixture was acidified with IN HCl (30 mL) and extracted with EtOAc (3 x 10 mL).
- Step 3 (5- ⁇ 2-[4-Oxo-5-(trifluoromethyl)-3,4-dihydro-r//-spiro[l,3-benzoxazine-2,4'-piperidin]- r-yll-l,3-thiazol-5-yl)-2H-tetrazol-2-yl)acetic acid.
- Step 1 3-Chloro-2-hvdroxybenzamide.
- a mixture of 3-chloro-2-hydroxybenzoic acid (335 mg, 1.94 mmol), DIPEA (2.98 niL, 17.08 mmol), HATU (849 mg, 2.232 mmol) was dissolved in DMF (1.94 mL)/THF (7.77 mL). The reaction was stirred for 15 min, then ammonium chloride (457 mg, 8.54 mmol) was added. The reaction mixture was stirred at room temperature overnight. The volatiles were evaporated under reduced pressure. The residue was diluted with saturated IN HCl (20 mL) and extracted with EtOAc (3 x 5 mL).
- Step 2 ⁇ EthvU5-[2-(8-chloro-4-oxo-3,4-dihvdro-rH-spiro[l,3-benzoxazine-2,4'-piperi din]-l'- vD- 1 ,3 -thiazol-5-yl] -2//-tetrazol-2-yl ⁇ acetate.
- the title compound was prepared in a similar manner as that described for Example 49 (step 3) from Intermediate 17 and 3-chloro-2- hydroxybenzamide.
- Step 3 ⁇ 5-r2-(8-Chloro-4-oxo-3,4-dihvdro-l 'i/-spiro ⁇ ,3-benzoxazine-2,4'-piperidin1-l'-yl)-l,3- thiazol-5-yll-2H-tetrazol-2-vU acetic acid.
- the title compound was prepared in a similar manner as that described for Example 9 (step 2) from ⁇ ethyl ⁇ 5-[2-(8-chloro-4-oxo-3,4-dihydro-17/- spiro [ 1 ,3 -benzoxazine-2,4'-piperi din] - 1 '-yl)- 1 ,3 -thiazol-5-yl] -2H-tetrazol-2-yl ⁇ acetate and LiOH.
- Step 2 Benzyl 5-methyl-4-oxo-3,4-dihydro-l 'H-spiro I " 1 ,3-benzoxazine-2,4'-piperidinel-l ⁇ carboxylate.
- the title compound was prepared in a similar manner as that described for Example 49 (step 3) from 2-hydroxy-6-methylbenzamide and benzyl 4-oxopiperidine-l -carboxylate.
- Step 3 5-Methylspiro[l J-benzoxazine-2,4'-piperidin1-4(3)-one.
- benzyl 5- methyl-4-oxo-3,4-dihydro-l'H-spiro[l,3-benzoxazine-2,4'-piperidine]-l '-carboxylate 293 mg, 0.80 mmol
- Pd/C 85 mg, 0.80 mmol
- H 2 (1.61 mg, 0.80 mmol
- Step 4 fert-Butyl ⁇ 5- F3 -(5 -methyl -4-QXQ-3 ,4-dihydro- 1 'H-spiro [ 1 ,3 -benzoxazine-2,4'-piperidin] - 1 '-yl)-4,5- dihydroisoxazol-5 -yl] -2H-tetrazol-2-yl ) acetate.
- Step 5 tert-Butyl ⁇ 5-r3-(5-methyl-4-oxo-3.4-dihvdro-rH-spiron,3-benzoxazine-2,4'-piperi din]-r-yl)isoxazol-5-yl]-2//-tetrazol-2-yUacetate.
- Step 6 ⁇ 5 -F3 -(5 -Methyl-4-oxo-3.4-dihydro- 1 'H-spiro ⁇ 1 ,3 -benzoxazine-2,4'-piperidinl- 1 '- yl)isoxazol-5 -yl] -2H-tetrazol-2-yl ⁇ acetic acid.
- Step 1 Benzyl 5-hvdroxy-4-oxo-3,4-dihvdro-rH-spiro[chromene-2,4'-piperidine1-r-carboxylate
- benzyl 4-oxopiperidine-l-carboxylate 2.67 g, 11.45 mmol
- methanol 25 ml
- hydroxyphenone 2.07 g, 13.61 mmol
- the reaction was stirred at 0 °C for Ih, then quenched at 0 °C by the addition of acetone.
- the reaction was diluted with DCM, washed with 5% KHSO 4 , dried over MgSO 4 , filtered and concentrated to give the title compound as a white foam.
- Step 3 Benzyl 5-ethoxy-4-hydroxy-3,4-dihvdro-l ⁇ -spiro
- a solution of benzyl 4,5-dihydroxy-3,4-dihydro- 1 ⁇ -spiro[chromene-2,4'-piperidine]- 1 '-carboxylate (570 mg, 1.54 mmol) in DME (5 ml) was treated with potassium carbonate (639 mg, 4.62 mmol), followed by neat ethyl bromide (1700 mg, 15.6 mmol).
- Step 4 5-Ethoxy-3,4-dihydrospiro[chromene-2,4'-piperidinel
- benzyl 5-ethoxy- 4-hydroxy-3,4-dihydro-l ⁇ -spiro[chromene-2,4'-piperidine]-r-carboxylate was added solid 10% Pd on carbon (350 mg, 21 mol%), followed by the addition of MeOH (60 ml) via a cannula.
- reaction was stirred under vacuum for 3 min. A balloon filled with H 2 was attached to the reaction vessel and the reaction mixture was stirred under a hydrogen atmosphere at room temperature for 1 h. Then 10 M HCl (0.4 mL, 4 mmol) was added, and the reaction was stirred under a H 2 atmosphere overnight. The reaction mixture was then filtered through a pad of CeliteTM and concentrated. The resulting mixture was dissolved in DCM and washed with IM NaOH in water, dried over MgSO 4 , filtered and concentrated to give the title compound.
- Step 5 tert-butyl [5-( ⁇ r(5-ethoxy-3,4-dihydro-r H -spirorchromene-2,4'-piperidinl-r-yl)(imino) methyl] sulfanyl ⁇ methyl)-2-H-tetrazol-2-yl] acetate
- a mixture of 5-ethoxy-3,4- dihydrospiro[chromene-2,4'-piperidine] (78 mg, 0.315 mmol)
- tert-butyl [5-(2-bromo-l,3-thiazol- 5-yl)-2H-tetrazol-2-yl]acetate 96 mg, 0.277 mmol
- K 2 CO 3 127 mg, 0.919 mmol
- reaction vial was sealed and the reaction was stirred under N 2 at external temperature of 110 °C for 2.5 h.
- the reaction was then cooled, diluted with EtOAc, washed with sat. NaHCO 3 and water, dried over MgSO 4 , filtered and concentrated.
- the resulting brown oily residue was purified by flash chromatography on silica gel (eluting with 5% to 50% EtOAc in hexane) to give the title compound as a pale yellow solid.
- Step 6 ⁇ 5-r2-(5-ethoxy-3.4-dihvdro-l ⁇ -spirorchromene-2,4'-piperidinl-r-yl)-l,3-thiazol-5-yl1- 2H-tetrazol-2-vU acetic acid
- tert-butyl [5-( ⁇ [(5-ethoxy-3,4-dihydro-l' H - spiro [chromene-2,4'-piperidin] - 1 '-yl)(imino) methyl] sulfanyl ⁇ methyl)-2H-tetrazol-2-yl] acetate (5.1 mg, 9.95 ⁇ mol) in THF (1 ml) and ethanol (0.5 ml) was added a solution of NaOH (10 mg, 0.250 mmol) in water (0.25 ml).
- Step 1 3,4-Dihydrospiro[chromene-2,4'-piperidin]-5-ol
- benzyl 4,5 -dihydroxy- 3,4-dihydro-l'H-spiro[chromene-2,4'-piperidine]-r-carboxylate 853 mg, 2.31 mmol
- solid 10% Pd on carbon 361 mg, 15 mol%)
- 10 M HCl in water 2mL, 20 mmol
- Step 2 r-(5-Bromo-l,3-thiazol-2-yl)-3,4-dihvdrospiro
- chromene-2,4'-piperidinl-5-ol A mixture of 3,4-dihydrospiro[chromene-2,4'-piperidin]-5-ol (504 mg, 2.30 mmol), 2,5- dibromothiazole (583 mg, 2.400 mmol), and K 2 CO 3 (795 mg, 5.75 mmol) was suspended in dry DMSO (5 ml), and stirred under N 2 at an external temperature of 110 0 C for 2 h. The reaction mixture was then cooled down to room temperature, and poured on 5% KHSO 4
- Step 3 r-(5-bromo-l,3-thiazol-2-yl)-5-(cyclopropylmethoxy)-3,4-dihydrospiro rchromene-2,4'- piperidine "
- l'-(5-bromo-l,3-thiazol-2-yl)-3,4- dihydrospiro[chromene-2,4'-piperidin]-5-ol (227 mg, 0.595 mmol) and triphenylphosphine (356 - -
- Step 4 Ethyl (3- ⁇ 2-[5-(cvclopropylmethoxy)-3,4-dihvdro- 1 'H-spiro[chromene-2,4'-piperidin ⁇ l- 1 '- yl] - 1 ,3 -thiazol-5 -yl ) -2-oxo-2,3 -dihydro- 1 H-imidazol- 1 -yl)acetate
- a mixture l'-(5-bromo-l,3- thiazol-2-yl)-5-(cyclopropylmethoxy)-3,4-dihydrospiro [chromene-2,4'-piperidine]hromene-2,4'- piperidine] (61.5 mg, 0.141 mmol), 2-imidazolone (41 mg, 0.241 mmol), copper(I) iodide (25 mg, 0.131 mmol) and potassium phosphate tribasic (104 mg
- the reaction mixture was treated with neat dimethyl ethylenediamine (24.68 mg, 0.28 mmol) in a sealed vial, which was covered with aluminum foil and placed in an oil bath preheated to 95 °C. The mixture was stirred at 95 0 C for 3.5 h, then diluted with DCM, washed with sat. NH 4 Cl plus some 5% KHSO 4 , dried over MgSO 4 , filtered and concentrated. The resulting oily residue was purified by flash chromatography on silica gel (eluting with 10% to 100% EtOAc in hexane) to give the title compound as a white solid.
- Step 5 (3- ⁇ 2-[5-(cvclopropylmethoxy)-3,4-dihydro- 17f-spiro[chromene-2,4'-piperidin "
- ethyl 3- ⁇ 2-[5- (cyclopropylmethoxy)-3,4-dihydro-rH-spiro[chromene-2,4'-piperidin]-r-yl]-l,3-thiazol-5-yl ⁇ -2- oxo-2,3-dihydro-lH-imidazol-l-yl)acetate (38 mg, 0.072 mmol) in THF (1.5 ml) and ethanol (1 ml), stirred at 0 °C, was treated with a solution
- reaction was stirred at 0 °C for 1.5 h.
- the reaction mixture was then diluted with DCM, washed with a solution of 5% KHSO 4 in water, dried over MgSO 4 , filtered and concentrated to provide a residue, which was further triturated with ether-hexane, filtered and dried to give the title compound as a white solid.
- Example 59 was prepared according to the synthesis described in Example 16.
- Examples 60 and 61 were prepared according to the synthesis described in Example 57.
- Examples 63, 64 and 65 were prepared according to the synthesis described in Example 21.
- Example 62 was prepared by the alkylation of the compound of Example 63 with 3,4- difluorobenzyl bromide.
- Step 1 Ethyl 3-(5-chloro-3,4-dihvdro-l'H-spirorchromene-2,4'-piperidinl-l'-yl)-4,5- dihydroisoxazole-5-carboxylate
- step 1 3-bromo-4,5-dihydroisoxazole-5-carboxylate from Example 2, step 1 (3.37 g, 15 mmol), 5-chloro-3,4-dihydrospiro[chromene-2,4'-piperidine] (3.8 g, 16 mmol) and DIPEA (5.8 g, 45 mmol) in EtOH (30 mL) was refluxed overnight.
- Step 2 3 -(5 -Chloro-3 ,4-dihydro- 1 '//-spiro [chromene-2,4'-piperidin] - 1 '-ypisoxazole-S-carboxylic acid
- a mixture of ethyl 3-(5-chloro-3,4-dihydro-l'//-spiro[chromene-2,4'-piperidin]-r-yl)- 4,5-dihydroisoxazole-5-carboxylate (2.53 g, 6.7 mmol)
- NaOAc (1.43 g, 17.4 mmol) in chlorobenzene (20 mL) was added I 2 (2.2 g, 8.7 mmol).
- Step 3 S-fS-Chloro-S ⁇ -dihydro-rH-spirol ' chromene ⁇ '-piperidinl-r-v ⁇ isoxazol-S-amine
- TEA 1.5 mL, 11 mmol
- 2-methylpropan-2-ol 20.2 g, 273 mmol
- DPPA 7.5 g, 27.3 mmol
- Step 4 1 - [3 -(5-Chloro-3 ,4-dihydro- 1 'H-spiro [chromene-2,4'-piperidinl - 1 '-yl)isoxazol-5-yl] - 1,3- dihydro-2H-imidazol-2-one
- 3-(5-chloro-3,4-dihydro-rH-spiro[chromene-2,4'- piperidin]-r-yl)isoxazol-5-amine 790 mg, 2.47 mmol
- DMAP (30 mg, 0.247 mmol)
- pyridine (215 mg, 2.72 mmol)
- phenyl carbonochloridate (464 mg, 2.97 mmol) in portions at O 0 C.
- Step 5 ⁇ 3 - [3 -(5 -Chloro-3 ,4-dihydro- 1 'H-spiro rchromene-2,4'-piperidin
- Step 1 3,4-Dihydrospiro[chromene-2,4'-piperidinel TFA salt
- Step 2 ⁇ 3 - [3 -(3 ,4-Dihydro- 1 'H-spiro [chromene-2,4'-piperidin1 - 1 '-yl)isoxazol-5-yl]-2-oxo-2,3 - dihydro- 1 H-imidazol- 1 -yl ⁇ acetic acid
- the title compound was prepared in a similar manner as described for Example 66 from 3,4- dihydrospiro[chromene-2,4'-piperidine] TFA salt and 3- bromo-4,5-dihydroisoxazole-5-carboxylate.
- Step 1 r-(5-Bromo-l,3-thiazol-2-yl)-5-chloro-3,4-dihvdrospirorchromene-2,4'-piperidine1
- 2,5-dibromothiazole 0.75 g, 4.01 mmol
- 5-chloro-3,4-dihydrospiro[chromene-2,4'- piperidine] HCl salt 1 g, 3.65 mmol
- DBU 1.3 mL, 8.62 mmol
- Step 2 Ethyl ⁇ 3 - [2-f 5 -chloro-3.4-dihydro- 1 'H-spiro rchromene-2,4'-piperidinl - 1 '-vD- 1 ,3 -thiazol- 5 -yl]-2-oxo-2,3-dihvdro-l H-imidazol- 1-vU acetate
- 2-dram vial was added l'-(5-bromo-l,3- thiazol-2-yl)-5 -chloro-3, 4-dihydrospiro[chromene-2,4'-piperidine] (250 mg, 0.625 mmol), ethyl (2-oxo-2,3 -dihydro- 1 H-imidazol- l-yl)acetate (117 mg, 0.67 mmol), potassium phosphate tribasic (266 mg, 1.25 mmol) and copper(i) iodide (
- Step 3 ⁇ 3-r2-(5-Chloro-3,4-dihvdro- 1 'H-spiro rchromene-2,4'-piperidin
- ethyl ⁇ 3-[2-(5-chloro-3,4- dihydro- 1 'H-spiro [chromene-2,4'-piperidin] - 1 '-yl)- 1 ,3 -thiazol-5-yl] -2-oxo-2,3 -dihydro- 1 H- imidazol-1-yl ⁇ acetate (140 mg, 0.29 mmol) in THF (4 mL) and MeOH (1 mL) was added IN NaOH (0.6 mL, 0.60 mmol).
- Step 1 Ethyl ⁇ 5-r2-(5-chloro-4-fluoro-3,4-dihvdro-rH-spirorchromene-2,4'-piperidin1-r-ylV l,3-thiazol-5-yl1-2//-tetrazol-2-yl)acetate
- step 1 200 mg, 0.4 mmol
- T ⁇ F 8 mL
- NaBH 4 5.7 mg, 0.149 mmol
- Step 2 ⁇ 5-r2-(5-Chloro-4-fluoro-3,4-dihvdro-r//-spirorchromene-2.4'-pi ⁇ eridin1-r-vn-l,3- thiazol-5 -yl] -2H-tetrazol-2-yl I acetic acid
- the title compound was prepared in a similar manner as that described for Example 9 Step 2 from ethyl ⁇ 5-[2-(5-chloro-4-fluoro-3,4-dihydro-177- spiro [chromene-2,4'-piperidin]- 1 '-yl)- 1 ,3 -thiazol-5 -yl] -2//-tetrazol-2-yl ⁇ acetate.
- Example 13 The title compound was prepared in a similar as described for Example 69 from ⁇ 5-[5-(5- chloro-4-oxo-3 ,4-dihydro- 1 'H-spiro [chromene-2,4'-piperidin] - 1 '-yl)- 1 ,3 ,4-thiadiazol-2-yl] -2H- tetrazol-2-yl ⁇ acetic acid (Example 13).
- Step 1 tert-Butyl 5-chloro-3-methyl-4-oxo-3,4-dihydro-rH-spiro[ " chromene-2,4'-piperidinel-r- carboxylate
- a solution of Li ⁇ MDS (0.37 mL, 0.37 mmol, 1.0 M/T ⁇ F) in T ⁇ F (0.3 mL) at - 78 0 C was added tert-buty ⁇ 5-chloro-4-oxo-3,4-dihydro-l ⁇ -spiro[criromene-2,4'-piperidine]-r- carboxylate (Intermediate 1, step 2), and (100 mg, 0.29 mmol) in THF (0.8 mL) under Argon.
- Step 2 5-Chloro-3-methylspirorcriromene-2,4'-piperidin1-4(3H)-one hydrochloride
- Step 3 fert-Butyl ⁇ 5-[2-(5-chloro-3-methyl-4-oxo-3,4-dihvdro-17/-spiro[chromene-2,4'- piperidinl-r-yl)-l,3-thiazol-5-yll-2H-tetrazol-2-vUacetate
- 5-chloro-3- methylspiro[chromene-2,4'-piperidin]-4(3H)-one hydrochloride 0.2 g, 0.664 mmol
- tert- butyl [5-(2-bromo-l,3-thiazol-5-yl)-2//-tetrazol-2-yl]acetate Intermediate 3, (0.23 g, 0.664 mmol) in DMF (4 mL) was added K 2 CO 3 (0.366 g, 2.56 mmol) under a nitrogen atmosphere.
- Step 4 ⁇ 5 - r2-(5-Chloro-3 -methyl-4-oxo-3 ,4-dihydro- 1 '/f-spiro rchromene-2,4'-piperidinl - 1 '-vD- 1 ,3-thiazol-5-yl]-2H-tetrazol-2-vU acetic acid
- the title compound was prepared in a similar manner as described above for step 2 of this example from tert-butyl ⁇ 5-[2-(5-chloro-3-methyl-4- oxo-3,4-dihydro-r//-spiro[chromene-2,4'-piperidin]-r-yl)-l,3-thiazol-5-yl]-2//-tetrazol-2- yl ⁇ acetate with HCl in dioxane.
- Step l Ethyl [4-(tributylstannyl)- 1 H- 1 ,2,3 -triazol- 1 -yl] acetate A mixture of ethyl azidoacetate (1.72 g, 13.3 mmol) and tributyl(ethynyl)stannane (4.20 g, 13.3 mmol) in 30 mL of anhydrous toluene was refluxed for 24 hours.
- Step 2 5 -(5-Chloro-3.4-dihvdro- 177-spiro
- TFA salt of Intermediate 1 0.6 g, 1.8 mmol
- 5-bromo-l,3,4-thiadiazol-2-amine 0.32 g, 1.8 mmol
- the mixture was stirred at 65 0 C for 2 hours.
- Step 3 r-(5-Bromo-l,3,4-thiadiazol-2-yl)-5-chloro-3,4-dihvdrospiro[chromene-2,4'-piperidine1
- a mixture Of CuBr 2 (0.34 g, 1.54 mmol) and anhydrous CH 3 CN (10 ml) was purged with argon and cooled to O 0 C with an ice bath, then t-BuONO (0.207 g, 2 mmol) was added dropwise.
- Step 4 Ethyl ⁇ 4-r5-(5-chloro-3,4-dihvdro-r//-spirorchromene-2,4'-piperidinl-r-yl)-L3,4- thiadiazol-2-yli - 1 H- 1 ,2,3 -triazol- 1 -yl ⁇ acetate
- a mixture of l'-(5-bromo-l,3,4-thiadiazol-2-yl)-5- chloro-3,4-dihydrospiro[chromene-2,4'-piperidine] 400 mg, 1 mmol
- ethyl [4-(tributylstannyl)- lH-l,2,3-triazol-l-yl]acetate (625 mg, 1.4 mmol)
- Pd(PPh 3 ) 4 115 mg, 0.1 mmol
- Step 5 ⁇ 4- [5 -(5-Chloro-3 ,4-dihydro- 1 'H-spiro
- the title compound was prepared in a similar manner as that described for Example 9 Step 2 from ethyl ⁇ 4-[5-(5-chloro-3,4-dihydro-l'H-spiro[chromene- 2,4'-piperidin]-l'-yl)-l,3,4-thiadiazol-2-yl]-lH-l,2,3-triazol-l-yl ⁇ acetate.
- Step 2 ferr-ButvU5-(2-r4-oxo-5-(trifluoromethyl)-3,4-dihvdro-rH-spirorchromene-2,4'- piperidini - 1 '-yl] - 1 ,3 -thiazol-5 -yl ) -2//-tetrazol-2-yl)acetate To a suspension of 5-
- Step 3 (5 - (244-0x0-5 -(trifluoromethyl)-3 ,4-dihvdro- 1 '//-spiro rchromene-2,4'-piperidinl - 1 '-yll - 1 ,3-thiazol-5-yl ⁇ -2H-tetrazol-2-yl)acetic acid
- tert-butyl (5- ⁇ 2-[4-oxo-5- (trifluoromethy ⁇ -S ⁇ -dihydro-rH-spirofchromene-l ⁇ '-piperidi ⁇ -r-y ⁇ -l j S-thiazol-S-ylj ⁇ H- tetrazol-2-yl)acetate (300 mg, 0.55 mmol) in THF (5 mL) and MeOH (1 niL) was added a solution of IM aqueous NaOH (1.1 mL, 1.1 mmol).
- Step 2 Ethyl 4-(5-chloro-3,4-dihvdro-r//-spirorchromene-2,4'-piperidin1-r-yl)-2-oxo-4- thioxobutanoate
- diethyl oxalate 1 mL, 7.3 mmol
- 5-chloro-l'-ethanethioyl-3,4- dihydrospiro[chromene-2,4'-piperidine] (1.8 g, 6.1 mmol) and dibenzo-18-C-6 (110 mg, 0.3 mmol) in THF (30 mL).
- Step 3 Ethyl 5-(5-chloro-3,4-dihvdro-rH-spirorchromene-2,4'-piperidin]-r-yl)isoxazole-3- carboxylate
- ethyl 4-(5-chloro-3,4-dihydro-177-spiro[chromene-2,4'-piperidin]-r- yl)-2-oxo-4-thioxobutanoate (1 g, 2.5 mmol), hydroxylamine hydrochloride (211 mg, 2.5 mmol), and NaHCO 3 (276 mg, 3.3 mmol) in EtOH (20 mL) was refluxed for 2h.
- Step 4 5-(5-Chloro-3,4-dihydro-r//-spiro
- ethyl 5-(5-chloro-3,4-dihydro-17/-spiro[chromene-2,4'-piperidin]- l'-yl)isoxazole-3-carboxylate 500 mg, 1.3 mmol
- MeOH 1 mL
- ammonium hydroxide 1.5 mL, 38.5 mmol
- Step 5 ⁇ 5-[5-(5-Chloro-3,4-dihvdro-r//-spiro[chromene-2,4'-piperidinl-r-yl)isoxa2ol-3-yl]-2H- tetrazol-2-yU acetic acid
- the title compound was prepared in a similar manner as described for Example 2, steps 5 and 6, from 5-(5-chloro-3,4-dihydro-17f-spiro[criromene-2,4'-piperidin]-r- yl)isoxazole-3-carboxamide.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2750564A CA2750564A1 (en) | 2009-02-17 | 2010-02-16 | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
US13/148,985 US9168248B2 (en) | 2009-02-17 | 2010-02-16 | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
EP10743365.8A EP2398809B1 (en) | 2009-02-17 | 2010-02-16 | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
ES10743365.8T ES2545864T3 (es) | 2009-02-17 | 2010-02-16 | Nuevos compuestos espiránicos útiles como inhibidores de la estearoil-coenzima A delta-9 desaturasa |
JP2011549410A JP5597210B2 (ja) | 2009-02-17 | 2010-02-16 | ステアロイル−補酵素aデルタ−9デサチュラーゼの阻害剤として有用な新規スピロ化合物 |
AU2010215035A AU2010215035B2 (en) | 2009-02-17 | 2010-02-16 | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20778409P | 2009-02-17 | 2009-02-17 | |
US61/207,784 | 2009-02-17 | ||
US24928409P | 2009-10-07 | 2009-10-07 | |
US61/249,284 | 2009-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010094120A1 true WO2010094120A1 (en) | 2010-08-26 |
Family
ID=42633388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2010/000218 WO2010094120A1 (en) | 2009-02-17 | 2010-02-16 | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
Country Status (7)
Country | Link |
---|---|
US (1) | US9168248B2 (es) |
EP (1) | EP2398809B1 (es) |
JP (1) | JP5597210B2 (es) |
AU (1) | AU2010215035B2 (es) |
CA (1) | CA2750564A1 (es) |
ES (1) | ES2545864T3 (es) |
WO (1) | WO2010094120A1 (es) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2398796A1 (en) * | 2009-02-23 | 2011-12-28 | Merck Canada Inc. | Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
EP2459568A1 (en) * | 2009-07-28 | 2012-06-06 | Merck Frosst Canada Limited | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
WO2013056148A2 (en) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
WO2013104561A1 (en) | 2012-01-12 | 2013-07-18 | Basf Se | Herbicidal isoxazolo[5,4-b]pyridines |
US20140065070A1 (en) * | 2012-08-28 | 2014-03-06 | Mcmaster University | Methods of preparing triazole-containing radioiodinated compounds |
WO2014117920A1 (en) | 2013-02-04 | 2014-08-07 | Merck Patent Gmbh | Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions |
US9233102B2 (en) | 2012-03-07 | 2016-01-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
CN108752360A (zh) * | 2018-04-12 | 2018-11-06 | 牡丹江医学院 | 一种治疗小儿腹泻的化合物及其制备方法 |
US10973810B2 (en) | 2017-01-06 | 2021-04-13 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
WO2023170699A1 (en) * | 2022-03-07 | 2023-09-14 | Ghatpande Nitin | Tricyclic spiro[chromane-2,4'-piperidin]-4(3h)-one with 1,3,4-oxadiazole linkers compositions and process for preparation thereof. |
US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3068623A1 (en) * | 2017-06-30 | 2019-01-03 | Quixgen, Inc. | Novel spirolactone compounds |
CN112679374A (zh) * | 2021-01-12 | 2021-04-20 | 湖南复瑞生物医药技术有限责任公司 | 2-氟-6-(三氟甲基)苯甲酰胺的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008056687A1 (fr) * | 2006-11-09 | 2008-05-15 | Daiichi Sankyo Company, Limited | Nouveau dérivé de spiropipéridine |
WO2008064474A1 (en) * | 2006-12-01 | 2008-06-05 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
US20100069351A1 (en) * | 2007-02-06 | 2010-03-18 | Takahiko Taniguchi | Spiro compound and use thereof |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003302640B2 (en) * | 2002-11-29 | 2009-09-24 | Banyu Pharmaceutical Co., Ltd. | Novel azole derivatives |
BRPI0413059A (pt) | 2003-07-29 | 2006-10-31 | Xenon Pharmaceuticals Inc | derivados de piridila e seu uso como agentes terapêuticos |
AU2004261267B9 (en) | 2003-07-30 | 2009-04-09 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
BRPI0412348A (pt) | 2003-07-30 | 2006-09-05 | Xenon Pharmaceuticals Inc | derivados de piperazina e seu uso como agentes terapêuticos |
US7754711B2 (en) | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
DK1648874T3 (da) | 2003-07-30 | 2012-01-23 | Xenon Pharmaceuticals Inc | Piperazinderivater samt deres anvendelse som terapeutisk aktive stoffer |
US7514436B2 (en) | 2003-07-30 | 2009-04-07 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
WO2006014168A1 (en) | 2004-07-06 | 2006-02-09 | Xenon Pharmaceuticals Inc. | Nicotinamide derivatives and their use as therapeutic agents |
CN101083982A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物 |
TW200626138A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
AU2005329423A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
JP4958786B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
AR051091A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
CN101083992A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物 |
WO2006034446A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridine derivatives for inhibiting human stearoyl-coa-desaturase |
WO2006034441A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
JP5080256B2 (ja) | 2004-09-20 | 2012-11-21 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 二環式複素環誘導体およびステアロイル−CoAデサチュラーゼ(SCD)のインヒビターとしてのそれらの使用 |
GT200600046A (es) | 2005-02-09 | 2006-09-25 | Terapia de combinacion | |
GB0504556D0 (en) * | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
WO2006125180A1 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
WO2006125178A2 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic pyridazine compounds and their uses as therapeutic agents |
WO2006125179A1 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
WO2007050124A1 (en) | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
WO2007046867A2 (en) | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
WO2007046868A2 (en) | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Thiazolidine derivatives and their uses as therapeutic agents |
WO2006125194A2 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
WO2006125181A2 (en) | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their use as stearoyl-coa desaturase modulators |
MX2007015216A (es) | 2005-06-03 | 2008-02-22 | Xenon Pharmaceuticals Inc | Derivados de aminotiazol y sus usos como agentes terapeuticos. |
WO2006130986A1 (en) | 2005-06-09 | 2006-12-14 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
US20090118296A1 (en) | 2005-07-20 | 2009-05-07 | Merck Frosst Canada Ltd. | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase |
WO2007056846A1 (en) | 2005-11-15 | 2007-05-24 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
JP2009519984A (ja) | 2005-12-20 | 2009-05-21 | メルク フロスト カナダ リミテツド | ステアロイル−補酵素δ−9デサチュラーゼ阻害剤としての芳香族複素環化合物 |
WO2007136746A2 (en) | 2006-05-19 | 2007-11-29 | Xenon Pharmaceuticals Inc. | Macrocyclic compounds and their uses as stearoyl-coa desaturase |
US20100004287A1 (en) | 2006-05-22 | 2010-01-07 | Merck Frosst Canada Ltd. | Cyclic Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase |
AU2007260527A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
CA2654098A1 (en) | 2006-06-13 | 2007-12-21 | Merck Frosst Canada Ltd. | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
WO2008003753A1 (en) | 2006-07-07 | 2008-01-10 | Biovitrum Ab (Publ) | Pyrazolo [1,5-a] pyrimidine analogs for use as inhibitors of stearoyl-coa desaturase (scd) activity |
US20090318476A1 (en) | 2006-08-09 | 2009-12-24 | Merck Frosst Canada Ltd. | Azacycloalkane Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase |
PE20110341A1 (es) | 2006-08-15 | 2011-06-21 | Novartis Ag | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA |
BRPI0719122A2 (pt) | 2006-08-24 | 2013-12-10 | Novartis Ag | Compostos orgânicos |
WO2008029266A1 (en) | 2006-09-08 | 2008-03-13 | Glenmark Pharmaceuticals S.A. | Stearoyl coa desaturase inhibitors |
CN101516877B (zh) | 2006-09-22 | 2013-09-11 | 诺瓦提斯公司 | 杂环有机化合物 |
WO2008044767A1 (fr) | 2006-10-13 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Dérivé d'amine aromatique et utilisation de celui-ci |
US20100004245A1 (en) | 2006-10-20 | 2010-01-07 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
WO2008062276A2 (en) | 2006-11-20 | 2008-05-29 | Glenmark Pharmaceuticals S.A. | Acetylene derivatives as stearoyl coa desaturase inhibitors |
AU2007336238A1 (en) | 2006-12-20 | 2008-06-26 | Novartis Ag | 2-substituted 5-membered heterocycles as SCD inhibitors |
GB0625594D0 (en) | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
AR064965A1 (es) | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
-
2010
- 2010-02-16 CA CA2750564A patent/CA2750564A1/en not_active Abandoned
- 2010-02-16 ES ES10743365.8T patent/ES2545864T3/es active Active
- 2010-02-16 US US13/148,985 patent/US9168248B2/en active Active
- 2010-02-16 EP EP10743365.8A patent/EP2398809B1/en active Active
- 2010-02-16 JP JP2011549410A patent/JP5597210B2/ja not_active Expired - Fee Related
- 2010-02-16 AU AU2010215035A patent/AU2010215035B2/en not_active Ceased
- 2010-02-16 WO PCT/CA2010/000218 patent/WO2010094120A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008056687A1 (fr) * | 2006-11-09 | 2008-05-15 | Daiichi Sankyo Company, Limited | Nouveau dérivé de spiropipéridine |
WO2008064474A1 (en) * | 2006-12-01 | 2008-06-05 | Merck Frosst Canada Ltd. | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
US20100069351A1 (en) * | 2007-02-06 | 2010-03-18 | Takahiko Taniguchi | Spiro compound and use thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP2398809A4 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2398796A1 (en) * | 2009-02-23 | 2011-12-28 | Merck Canada Inc. | Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
EP2398796A4 (en) * | 2009-02-23 | 2012-10-10 | Merck Canada Inc | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF THE STEAROYL COENZYME A DELTA 9 DESATURASE |
EP2459568A1 (en) * | 2009-07-28 | 2012-06-06 | Merck Frosst Canada Limited | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
EP2459568A4 (en) * | 2009-07-28 | 2013-02-27 | Merck Frosst Canada Ltd | NOVEL SPIRO COMPOUNDS USEFUL AS DELTA-9 DEATURASE STEAROYL COENZYME INHIBITORS |
WO2013056148A2 (en) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
US9358250B2 (en) | 2011-10-15 | 2016-06-07 | Genentech, Inc. | Methods of using SCD1 antagonists |
WO2013104561A1 (en) | 2012-01-12 | 2013-07-18 | Basf Se | Herbicidal isoxazolo[5,4-b]pyridines |
US9233102B2 (en) | 2012-03-07 | 2016-01-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
US10160972B2 (en) | 2012-03-07 | 2018-12-25 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
US20140065070A1 (en) * | 2012-08-28 | 2014-03-06 | Mcmaster University | Methods of preparing triazole-containing radioiodinated compounds |
WO2014117920A1 (en) | 2013-02-04 | 2014-08-07 | Merck Patent Gmbh | Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions |
US9708321B2 (en) | 2013-02-04 | 2017-07-18 | Merck Patent Gmbh | Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 |
US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
US10973810B2 (en) | 2017-01-06 | 2021-04-13 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
CN108752360A (zh) * | 2018-04-12 | 2018-11-06 | 牡丹江医学院 | 一种治疗小儿腹泻的化合物及其制备方法 |
WO2023170699A1 (en) * | 2022-03-07 | 2023-09-14 | Ghatpande Nitin | Tricyclic spiro[chromane-2,4'-piperidin]-4(3h)-one with 1,3,4-oxadiazole linkers compositions and process for preparation thereof. |
Also Published As
Publication number | Publication date |
---|---|
EP2398809A4 (en) | 2012-11-28 |
CA2750564A1 (en) | 2010-08-26 |
EP2398809B1 (en) | 2015-07-08 |
AU2010215035A1 (en) | 2011-07-28 |
US9168248B2 (en) | 2015-10-27 |
JP5597210B2 (ja) | 2014-10-01 |
EP2398809A1 (en) | 2011-12-28 |
JP2012517960A (ja) | 2012-08-09 |
US20110312952A1 (en) | 2011-12-22 |
ES2545864T3 (es) | 2015-09-16 |
AU2010215035B2 (en) | 2014-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010215035B2 (en) | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase | |
AU2007327276B2 (en) | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase | |
US7754745B2 (en) | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | |
WO2010108268A1 (en) | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase | |
US20090118296A1 (en) | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase | |
AU2010215041A1 (en) | Heterocyclic derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase | |
AU2007260527A1 (en) | Azetidine derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase | |
US8383643B2 (en) | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase | |
WO2011047481A1 (en) | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase | |
AU2011279509A1 (en) | Spirocyclic compounds | |
AU2007283401A1 (en) | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase | |
AU2008253512A1 (en) | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10743365 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010215035 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2750564 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2010215035 Country of ref document: AU Date of ref document: 20100216 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13148985 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010743365 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011549410 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |